WO2023282356A1 - Oral composition and prophylactic or treatment method for diseases of the oral cavity - Google Patents
Oral composition and prophylactic or treatment method for diseases of the oral cavity Download PDFInfo
- Publication number
- WO2023282356A1 WO2023282356A1 PCT/JP2022/027147 JP2022027147W WO2023282356A1 WO 2023282356 A1 WO2023282356 A1 WO 2023282356A1 JP 2022027147 W JP2022027147 W JP 2022027147W WO 2023282356 A1 WO2023282356 A1 WO 2023282356A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nite
- oral
- bacteria
- isolate
- lactobacillus plantarum
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 85
- 210000000214 mouth Anatomy 0.000 title claims abstract description 15
- 238000000034 method Methods 0.000 title claims description 25
- 230000000069 prophylactic effect Effects 0.000 title abstract description 4
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title description 5
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 72
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 61
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 61
- 238000004113 cell culture Methods 0.000 claims abstract description 39
- 239000000284 extract Substances 0.000 claims abstract description 29
- 241001465754 Metazoa Species 0.000 claims abstract description 12
- 241000894006 Bacteria Species 0.000 claims description 91
- 208000028169 periodontal disease Diseases 0.000 claims description 44
- 208000025157 Oral disease Diseases 0.000 claims description 25
- 208000030194 mouth disease Diseases 0.000 claims description 25
- 230000000844 anti-bacterial effect Effects 0.000 claims description 23
- 235000013305 food Nutrition 0.000 claims description 15
- 230000012010 growth Effects 0.000 claims description 14
- 239000003966 growth inhibitor Substances 0.000 claims description 10
- 239000003899 bactericide agent Substances 0.000 claims description 9
- 150000002222 fluorine compounds Chemical class 0.000 claims description 6
- 235000021107 fermented food Nutrition 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 241000605862 Porphyromonas gingivalis Species 0.000 claims description 4
- 241001135235 Tannerella forsythia Species 0.000 claims description 4
- 241000589892 Treponema denticola Species 0.000 claims description 4
- 239000000551 dentifrice Substances 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 239000002324 mouth wash Substances 0.000 claims description 4
- 229940051866 mouthwash Drugs 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 46
- 108020004465 16S ribosomal RNA Proteins 0.000 description 45
- 108090000623 proteins and genes Proteins 0.000 description 41
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 38
- 230000001580 bacterial effect Effects 0.000 description 32
- 238000002360 preparation method Methods 0.000 description 32
- 238000002474 experimental method Methods 0.000 description 27
- 239000002773 nucleotide Substances 0.000 description 25
- 125000003729 nucleotide group Chemical group 0.000 description 25
- 235000014655 lactic acid Nutrition 0.000 description 23
- 239000004310 lactic acid Substances 0.000 description 23
- 238000012360 testing method Methods 0.000 description 22
- 239000002609 medium Substances 0.000 description 19
- 241000233866 Fungi Species 0.000 description 17
- -1 etc.) Substances 0.000 description 17
- 235000011187 glycerol Nutrition 0.000 description 15
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 13
- 229920001817 Agar Polymers 0.000 description 12
- 238000012300 Sequence Analysis Methods 0.000 description 12
- 239000008272 agar Substances 0.000 description 12
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 11
- 238000003794 Gram staining Methods 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 10
- 241000186660 Lactobacillus Species 0.000 description 10
- 241000186684 Lactobacillus pentosus Species 0.000 description 10
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 10
- 229940039696 lactobacillus Drugs 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 230000036961 partial effect Effects 0.000 description 10
- 239000000049 pigment Substances 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 229960003511 macrogol Drugs 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000000654 additive Substances 0.000 description 8
- 244000005700 microbiome Species 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 102000016938 Catalase Human genes 0.000 description 7
- 108010053835 Catalase Proteins 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000000417 fungicide Substances 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical group OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 241000193830 Bacillus <bacterium> Species 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 229930091371 Fructose Natural products 0.000 description 6
- 239000005715 Fructose Substances 0.000 description 6
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000000996 additive effect Effects 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 229960003237 betaine Drugs 0.000 description 6
- 238000000855 fermentation Methods 0.000 description 6
- 230000004151 fermentation Effects 0.000 description 6
- 230000009036 growth inhibition Effects 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 238000006395 oxidase reaction Methods 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 108010082340 Arginine deiminase Proteins 0.000 description 5
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 5
- 241000866650 Lactobacillus paraplantarum Species 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 102000007544 Whey Proteins Human genes 0.000 description 5
- 108010046377 Whey Proteins Proteins 0.000 description 5
- 239000008186 active pharmaceutical agent Substances 0.000 description 5
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 229930182830 galactose Natural products 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- 108010074461 nisin A Proteins 0.000 description 5
- 230000007505 plaque formation Effects 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 241000186361 Actinobacteria <class> Species 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 102000011632 Caseins Human genes 0.000 description 4
- 108010076119 Caseins Proteins 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 241001135786 Lactobacillus cerevisiae Species 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 239000003082 abrasive agent Substances 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000012136 culture method Methods 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 208000002925 dental caries Diseases 0.000 description 4
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000003449 preventive effect Effects 0.000 description 4
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000606 toothpaste Substances 0.000 description 4
- 229940034610 toothpaste Drugs 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 3
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 3
- 241000194036 Lactococcus Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- 239000004098 Tetracycline Substances 0.000 description 3
- 229960000458 allantoin Drugs 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 3
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000001332 colony forming effect Effects 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- HOVAGTYPODGVJG-VEIUFWFVSA-N methyl alpha-D-mannoside Chemical compound CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O HOVAGTYPODGVJG-VEIUFWFVSA-N 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 235000019830 sodium polyphosphate Nutrition 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 229960002180 tetracycline Drugs 0.000 description 3
- 229930101283 tetracycline Natural products 0.000 description 3
- 235000019364 tetracycline Nutrition 0.000 description 3
- 150000003522 tetracyclines Chemical class 0.000 description 3
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 3
- 235000021119 whey protein Nutrition 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical group OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 description 2
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 2
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 208000006558 Dental Calculus Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 208000005232 Glossitis Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 206010028116 Mucosal inflammation Diseases 0.000 description 2
- 201000010927 Mucositis Diseases 0.000 description 2
- 108010053775 Nisin Proteins 0.000 description 2
- NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 description 2
- 208000007027 Oral Candidiasis Diseases 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 241001228709 Suruga Species 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 description 2
- 239000005862 Whey Substances 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 229910021536 Zeolite Inorganic materials 0.000 description 2
- KPQJOKRSYYJJEL-VLQRKCJKSA-K [Na+].[Na+].CC1(C)[C@H](CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C([O-])=O)O[C@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O)C([O-])=O)C([O-])=O Chemical compound [Na+].[Na+].CC1(C)[C@H](CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C([O-])=O)O[C@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O)C([O-])=O)C([O-])=O KPQJOKRSYYJJEL-VLQRKCJKSA-K 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 229940064004 antiseptic throat preparations Drugs 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 2
- 229960001950 benzethonium chloride Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000001055 blue pigment Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 230000000855 fungicidal effect Effects 0.000 description 2
- 208000007565 gingivitis Diseases 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000015243 ice cream Nutrition 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000000832 lactitol Substances 0.000 description 2
- 235000010448 lactitol Nutrition 0.000 description 2
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 2
- 229960003451 lactitol Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- 229940035436 maltitol Drugs 0.000 description 2
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 239000004309 nisin Substances 0.000 description 2
- 235000010297 nisin Nutrition 0.000 description 2
- 229940041667 oral paste Drugs 0.000 description 2
- 229940042126 oral powder Drugs 0.000 description 2
- 230000003239 periodontal effect Effects 0.000 description 2
- 201000001245 periodontitis Diseases 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 2
- 239000011775 sodium fluoride Substances 0.000 description 2
- 235000013024 sodium fluoride Nutrition 0.000 description 2
- 229960004711 sodium monofluorophosphate Drugs 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229940048086 sodium pyrophosphate Drugs 0.000 description 2
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- CCXAYLQLOLXXKE-DWJAGBRCSA-K trisodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4s,5s,6s)-2-[[(3s,4ar,6ar,6bs,8as,11s,12ar,14ar,14bs)-11-carboxylato-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl]oxy]-6-carboxylato-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-t Chemical compound [Na+].[Na+].[Na+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C([O-])=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O CCXAYLQLOLXXKE-DWJAGBRCSA-K 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 239000010457 zeolite Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- QYIXCDOBOSTCEI-QCYZZNICSA-N (5alpha)-cholestan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-QCYZZNICSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- BKUWWVKLLKXDJK-UHFFFAOYSA-N 2-(dimethylamino)icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCC(N(C)C)C(O)=O BKUWWVKLLKXDJK-UHFFFAOYSA-N 0.000 description 1
- XPALGXXLALUMLE-UHFFFAOYSA-N 2-(dimethylamino)tetradecanoic acid Chemical compound CCCCCCCCCCCCC(N(C)C)C(O)=O XPALGXXLALUMLE-UHFFFAOYSA-N 0.000 description 1
- SVIJYLPSHPPVQF-UHFFFAOYSA-N 2-[2,2-diaminoethyl(dodecyl)amino]acetic acid Chemical compound CCCCCCCCCCCCN(CC(N)N)CC(O)=O SVIJYLPSHPPVQF-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- AXCXHFKZHDEKTP-NSCUHMNNSA-N 4-methoxycinnamaldehyde Chemical compound COC1=CC=C(\C=C\C=O)C=C1 AXCXHFKZHDEKTP-NSCUHMNNSA-N 0.000 description 1
- DDFHBQSCUXNBSA-UHFFFAOYSA-N 5-(5-carboxythiophen-2-yl)thiophene-2-carboxylic acid Chemical compound S1C(C(=O)O)=CC=C1C1=CC=C(C(O)=O)S1 DDFHBQSCUXNBSA-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000606749 Aggregatibacter actinomycetemcomitans Species 0.000 description 1
- 240000002900 Arthrospira platensis Species 0.000 description 1
- 235000016425 Arthrospira platensis Nutrition 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- MOZDKDIOPSPTBH-UHFFFAOYSA-N Benzyl parahydroxybenzoate Chemical compound C1=CC(O)=CC=C1C(=O)OCC1=CC=CC=C1 MOZDKDIOPSPTBH-UHFFFAOYSA-N 0.000 description 1
- 241001473877 Biserrula isolate Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 244000178937 Brassica oleracea var. capitata Species 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000222178 Candida tropicalis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241001466804 Carnivora Species 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000238366 Cephalopoda Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- WJLVQTJZDCGNJN-UHFFFAOYSA-N Chlorhexidine hydrochloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- SEBIKDIMAPSUBY-ARYZWOCPSA-N Crocin Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)C(C)=CC=CC(C)=C\C=C\C=C(/C)\C=C\C=C(C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1)O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SEBIKDIMAPSUBY-ARYZWOCPSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 1
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- 239000000253 Denture Cleanser Substances 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000289659 Erinaceidae Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001329 FEMA 3811 Substances 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 241000605986 Fusobacterium nucleatum Species 0.000 description 1
- 240000001972 Gardenia jasminoides Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 235000005206 Hibiscus Nutrition 0.000 description 1
- 235000007185 Hibiscus lunariifolius Nutrition 0.000 description 1
- 244000284380 Hibiscus rosa sinensis Species 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- XPJVKCRENWUEJH-UHFFFAOYSA-N Isobutylparaben Chemical compound CC(C)COC(=O)C1=CC=C(O)C=C1 XPJVKCRENWUEJH-UHFFFAOYSA-N 0.000 description 1
- CMHMMKSPYOOVGI-UHFFFAOYSA-N Isopropylparaben Chemical compound CC(C)OC(=O)C1=CC=C(O)C=C1 CMHMMKSPYOOVGI-UHFFFAOYSA-N 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 241000218492 Lactobacillus crispatus Species 0.000 description 1
- 241000186606 Lactobacillus gasseri Species 0.000 description 1
- 241000186605 Lactobacillus paracasei Species 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- 241000283953 Lagomorpha Species 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Chemical group CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- CTEMZTQLPNKNKP-REGJXUDFSA-N Maltosyl trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O[C@@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)[C@@H](CO)O2)O)[C@@H](CO)O1 CTEMZTQLPNKNKP-REGJXUDFSA-N 0.000 description 1
- 108010070551 Meat Proteins Proteins 0.000 description 1
- 235000014749 Mentha crispa Nutrition 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 244000078639 Mentha spicata Species 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 241000228347 Monascus <ascomycete fungus> Species 0.000 description 1
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- HDVDLQFPDLTOSI-UHFFFAOYSA-L O[AlH]O Chemical compound O[AlH]O HDVDLQFPDLTOSI-UHFFFAOYSA-L 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 235000005308 Pandanus Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 244000062720 Pennisetum compressum Species 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- XCOJIVIDDFTHGB-UEUZTHOGSA-N Perillartine Chemical compound CC(=C)[C@H]1CCC(\C=N\O)=CC1 XCOJIVIDDFTHGB-UEUZTHOGSA-N 0.000 description 1
- 241000283089 Perissodactyla Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 235000005205 Pinus Nutrition 0.000 description 1
- 241000218602 Pinus <genus> Species 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- 241001135221 Prevotella intermedia Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 241000194026 Streptococcus gordonii Species 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 241000194024 Streptococcus salivarius Species 0.000 description 1
- 241000193987 Streptococcus sobrinus Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Chemical group 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Chemical group 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Chemical group C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Chemical group 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 241000222126 [Candida] glabrata Species 0.000 description 1
- YVZLYNHKJASIHA-UHFFFAOYSA-L [Na+].[K+].OP(O)([O-])=O.OP(O)([O-])=O Chemical compound [Na+].[K+].OP(O)([O-])=O.OP(O)([O-])=O YVZLYNHKJASIHA-UHFFFAOYSA-L 0.000 description 1
- MEYPRMGRFQCXHY-UHFFFAOYSA-N [Na].F[Si](F)(F)F Chemical compound [Na].F[Si](F)(F)F MEYPRMGRFQCXHY-UHFFFAOYSA-N 0.000 description 1
- OZAOTUWBEKTDTD-UHFFFAOYSA-N [Si](F)(F)(F)F.[Ca] Chemical compound [Si](F)(F)(F)F.[Ca] OZAOTUWBEKTDTD-UHFFFAOYSA-N 0.000 description 1
- AMZWNNKNOQSBOP-UHFFFAOYSA-M [n'-(2,5-dioxoimidazolidin-4-yl)carbamimidoyl]oxyaluminum;dihydrate Chemical compound O.O.NC(=O)NC1N=C(O[Al])NC1=O AMZWNNKNOQSBOP-UHFFFAOYSA-M 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 229960004220 alcloxa Drugs 0.000 description 1
- 229940015825 aldioxa Drugs 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical group OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 1
- QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- KKEMWYNNTBRYMR-UHFFFAOYSA-N azulene-1-sulfonic acid Chemical compound C1=CC=CC=C2C(S(=O)(=O)O)=CC=C21 KKEMWYNNTBRYMR-UHFFFAOYSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- LFYJSSARVMHQJB-QIXNEVBVSA-N bakuchiol Chemical compound CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1 LFYJSSARVMHQJB-QIXNEVBVSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 244000237250 bengkuang Species 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229940034794 benzylparaben Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229940043256 calcium pyrophosphate Drugs 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 208000032343 candida glabrata infection Diseases 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001746 carotenes Chemical group 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 210000000991 chicken egg Anatomy 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 229960004504 chlorhexidine hydrochloride Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- HWDGVJUIHRPKFR-UHFFFAOYSA-I copper;trisodium;18-(2-carboxylatoethyl)-20-(carboxylatomethyl)-12-ethenyl-7-ethyl-3,8,13,17-tetramethyl-17,18-dihydroporphyrin-21,23-diide-2-carboxylate Chemical compound [Na+].[Na+].[Na+].[Cu+2].N1=C(C(CC([O-])=O)=C2C(C(C)C(C=C3C(=C(C=C)C(=C4)[N-]3)C)=N2)CCC([O-])=O)C(=C([O-])[O-])C(C)=C1C=C1C(CC)=C(C)C4=N1 HWDGVJUIHRPKFR-UHFFFAOYSA-I 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229910002026 crystalline silica Inorganic materials 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- SPPIIOPGDLITJE-VLQRKCJKSA-N diazanium;(2s,3s,4s,5r,6s)-6-[[(3s,4ar,6ar,6bs,8as,11s,12ar,14ar,14bs)-11-carboxylato-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl]oxy]-5-[(2r,3r,4s,5s,6s)-6-carboxy-3,4,5-trihydroxyoxan-2-yl]oxy-3,4-dihy Chemical compound N.N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O SPPIIOPGDLITJE-VLQRKCJKSA-N 0.000 description 1
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- FXNRKXSSLJKNGH-UHFFFAOYSA-L dipotassium;fluoro-dioxido-oxo-$l^{5}-phosphane Chemical compound [K+].[K+].[O-]P([O-])(F)=O FXNRKXSSLJKNGH-UHFFFAOYSA-L 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 235000019820 disodium diphosphate Nutrition 0.000 description 1
- GYQBBRRVRKFJRG-UHFFFAOYSA-L disodium pyrophosphate Chemical compound [Na+].[Na+].OP([O-])(=O)OP(O)([O-])=O GYQBBRRVRKFJRG-UHFFFAOYSA-L 0.000 description 1
- CEYULKASIQJZGP-UHFFFAOYSA-L disodium;2-(carboxymethyl)-2-hydroxybutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O CEYULKASIQJZGP-UHFFFAOYSA-L 0.000 description 1
- LVXHNCUCBXIIPE-UHFFFAOYSA-L disodium;hydrogen phosphate;hydrate Chemical compound O.[Na+].[Na+].OP([O-])([O-])=O LVXHNCUCBXIIPE-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- QYIXCDOBOSTCEI-FBVYSKEZSA-N epidihydrocholesterin Chemical compound C([C@@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-FBVYSKEZSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000013611 frozen food Nutrition 0.000 description 1
- 239000008369 fruit flavor Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000009627 gardenia yellow Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229940113094 isopropylparaben Drugs 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- SUIQUYDRLGGZOL-RCWTXCDDSA-N levofloxacin hemihydrate Chemical compound O.C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1.C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 SUIQUYDRLGGZOL-RCWTXCDDSA-N 0.000 description 1
- 235000020888 liquid diet Nutrition 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- SXQCTESRRZBPHJ-UHFFFAOYSA-M lissamine rhodamine Chemical compound [Na+].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S([O-])(=O)=O)C=C1S([O-])(=O)=O SXQCTESRRZBPHJ-UHFFFAOYSA-M 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229940073475 lysozyme hydrochloride Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229960002337 magnesium chloride Drugs 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 229960002260 meropenem Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 1
- ITVGXXMINPYUHD-CUVHLRMHSA-N neohesperidin dihydrochalcone Chemical compound C1=C(O)C(OC)=CC=C1CCC(=O)C(C(=C1)O)=C(O)C=C1O[C@H]1[C@H](O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 ITVGXXMINPYUHD-CUVHLRMHSA-N 0.000 description 1
- 229940089953 neohesperidin dihydrochalcone Drugs 0.000 description 1
- 235000010434 neohesperidine DC Nutrition 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- ZVVSSOQAYNYNPP-UHFFFAOYSA-N olaflur Chemical compound F.F.CCCCCCCCCCCCCCCCCCN(CCO)CCCN(CCO)CCO ZVVSSOQAYNYNPP-UHFFFAOYSA-N 0.000 description 1
- 229960001245 olaflur Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940041672 oral gel Drugs 0.000 description 1
- 229940042125 oral ointment Drugs 0.000 description 1
- 229940041678 oral spray Drugs 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 235000013808 oxidized starch Nutrition 0.000 description 1
- 239000001254 oxidized starch Substances 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- AXCXHFKZHDEKTP-UHFFFAOYSA-N para-methoxycinnamaldehyde Natural products COC1=CC=C(C=CC=O)C=C1 AXCXHFKZHDEKTP-UHFFFAOYSA-N 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Chemical group CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 229940023488 pill Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229940051841 polyoxyethylene ether Drugs 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229940093956 potassium carbonate Drugs 0.000 description 1
- 239000011698 potassium fluoride Substances 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- YHLBDCUXFZRLFT-UHFFFAOYSA-N propane-1,1-diol;propane-1,3-diol Chemical compound CCC(O)O.OCCCO YHLBDCUXFZRLFT-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 229940005657 pyrophosphoric acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 229940072132 quinolone antibacterials Drugs 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 239000001054 red pigment Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- AZJPTIGZZTZIDR-UHFFFAOYSA-L rose bengal Chemical compound [K+].[K+].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 AZJPTIGZZTZIDR-UHFFFAOYSA-L 0.000 description 1
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940079841 sodium copper chlorophyllin Drugs 0.000 description 1
- 235000013758 sodium copper chlorophyllin Nutrition 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 235000019187 sodium-L-ascorbate Nutrition 0.000 description 1
- 239000011755 sodium-L-ascorbate Substances 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- DGPIGKCOQYBCJH-UHFFFAOYSA-M sodium;acetic acid;hydroxide Chemical compound O.[Na+].CC([O-])=O DGPIGKCOQYBCJH-UHFFFAOYSA-M 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 229940082787 spirulina Drugs 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- YUOWTJMRMWQJDA-UHFFFAOYSA-J tin(iv) fluoride Chemical compound [F-].[F-].[F-].[F-].[Sn+4] YUOWTJMRMWQJDA-UHFFFAOYSA-J 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229960005196 titanium dioxide Drugs 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 229950009883 tocopheryl nicotinate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- YSJNWPJHMDWGAA-UHFFFAOYSA-H tricalcium;[oxido-[oxido(phosphonatooxy)phosphoryl]oxyphosphoryl] phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O YSJNWPJHMDWGAA-UHFFFAOYSA-H 0.000 description 1
- VXYADVIJALMOEQ-UHFFFAOYSA-K tris(lactato)aluminium Chemical compound CC(O)C(=O)O[Al](OC(=O)C(C)O)OC(=O)C(C)O VXYADVIJALMOEQ-UHFFFAOYSA-K 0.000 description 1
- 229910000406 trisodium phosphate Inorganic materials 0.000 description 1
- 235000019801 trisodium phosphate Nutrition 0.000 description 1
- UJMBCXLDXJUMFB-UHFFFAOYSA-K trisodium;5-oxo-1-(4-sulfonatophenyl)-4-[(4-sulfonatophenyl)diazenyl]-4h-pyrazole-3-carboxylate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-UHFFFAOYSA-K 0.000 description 1
- 229960004747 ubidecarenone Drugs 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Chemical group O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 239000011720 vitamin B Chemical group 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Chemical group 0.000 description 1
- 150000003710 vitamin D derivatives Chemical group 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Chemical group 0.000 description 1
- 150000003721 vitamin K derivatives Chemical group 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- GFQYVLUOOAAOGM-UHFFFAOYSA-N zirconium(iv) silicate Chemical compound [Zr+4].[O-][Si]([O-])([O-])[O-] GFQYVLUOOAAOGM-UHFFFAOYSA-N 0.000 description 1
- 235000021249 α-casein Nutrition 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
- 239000004711 α-olefin Substances 0.000 description 1
- 235000021247 β-casein Nutrition 0.000 description 1
- 229930007845 β-thujaplicin Natural products 0.000 description 1
- 235000021246 κ-casein Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
Definitions
- the present invention relates to an oral composition and a method for preventing or treating oral diseases.
- Periodontal disease is caused by pathogenic microorganisms such as periodontal disease bacteria, and is an infectious disease that affects many humans. Compositions containing ingredients with antibacterial activity against pathogenic bacteria have been developed to control periodontal disease.
- Patent Document 1 one or more bacterial cells or bacterial cell cultures selected from Lactobacillus rhamnosus KO3 strain, Lactobacillus casei YU3 strain and Lactobacillus paracasei YU4 strain A prophylactic or therapeutic agent for oral diseases is disclosed, which contains a substance, etc. as an active ingredient.
- Patent Document 2 discloses a composition for preventing or treating oral diseases containing Kog1 or Kog3 produced from Lactobacillus rhamnosus KO1 strain and Lactobacillus rhamnosus KO3 strain. ing.
- Patent Document 3 discloses a toothpaste containing nisin.
- Patent Document 4 discloses an oral antibacterial composition comprising nisin and polylysine.
- German Patent Application Publication No. 102011116325 discloses a composition for oral care comprising cells of bacteria belonging to Lactobacillus crispatus, Lactobacillus gasseri and Lactobacillus acidophilus or parts thereof. is disclosed.
- An object of the present invention is to provide a novel composition capable of suppressing oral diseases.
- the present invention relates to items exemplified below.
- the Lactobacillus plantarum is at least one selected from NITE-BP-03198, NITE-BP-03199, NITE-BP-03200, NITE-BP-03201 and NITE-BP-03202, The composition according to any one of [1] to [5].
- a method for preventing or treating oral diseases which comprises applying Lactobacillus plantarum cells, cell cultures, or extracts thereof to the oral cavity of an animal.
- the method of [9] wherein the oral disease is periodontal disease.
- a growth inhibitor or bactericidal agent for periodontal disease-causing bacteria containing Lactobacillus plantarum cells, cell cultures, or extracts thereof.
- a method for inhibiting the growth of or sterilizing periodontal disease bacteria which comprises contacting Lactobacillus plantarum cells, cell cultures, or extracts thereof with periodontal disease-causing bacteria.
- FIG. 2 shows (A) colony shape and (B) Gram staining results of NITE BP-03198 in Experiment 1.
- FIG. Fig. 2 shows (A) colony shape and (B) Gram staining results of NITE BP-03199 in Experiment 2.
- FIG. 10 shows (A) colony shape and (B) Gram staining results of NITE BP-03200 in Experiment 3.
- FIG. 10 shows (A) colony shape and (B) Gram staining results of NITE BP-03201 in Experiment 4.
- FIG. FIG. 10 shows (A) colony shape and (B) Gram staining results of NITE BP-03202 in Experiment 5.
- FIG. FIG. 10 is a diagram illustrating an antibacterial activity evaluation test against bacteria in Experiments 6 to 8.
- composition for oral cavity An oral composition according to one embodiment of the present invention comprises cells or cell cultures of Lactobacillus plantarum or extracts thereof.
- the composition according to the present invention has antibacterial activity against periodontal bacteria.
- Lactobacillus plantarum is preferably at least one selected from NITE-BP-03198, NITE-BP-03199, NITE-BP-03200, NITE-BP-03201 and NITE-BP-03202.
- NITE-BP-03198, NITE-BP-03199, NITE-BP-03200, NITE-BP-03201 and NITE-BP-03202 are respectively accession number NITE BP-03198 (original deposit date: April 9, 2020) , Accession No. NITE BP-03199 (Original Deposit Date: April 9, 2020), Accession No. NITE BP-03200 (Original Deposit Date: April 9, 2020), Accession No.
- NITE BP-03201 (Original Deposit Date: April 9, 2020), under the accession number NITE BP-03202 (original deposit date: April 9, 2020), National Institute of Technology and Evaluation Patent Microorganisms Depositary Center (NPMD, Address: 292-0818 Chiba It is a bacterium that has been internationally deposited under the Budapest Treaty at Room 122, 2-5-8 Kazusa Kamatari, Kisarazu City, Prefecture. All of the above bacteria belong to Lactobacillus plantarum, which is a kind of lactic acid bacteria. The mycological properties of the bacteria are shown in Tables 1 to 10 and FIGS. 1 to 5, which will be described later.
- NITE-BP-03198 exists in fermented foods, and NITE-BP-03199, NITE-BP-03200, NITE-BP-03201 and NITE-BP-03202 exist in the natural environment, they are highly safe to humans. it is conceivable that.
- the lactic acid bacteria may be isolated bacteria.
- the oral composition according to one embodiment of the present invention is at least one selected from NITE-BP-03198, NITE-BP-03199, NITE-BP-03200, NITE-BP-03201 and NITE-BP-03202 bacteria or bacterial cell cultures or extracts thereof.
- the fungus may be isolated from the fermented food or the environment, or may be cultured.
- the cells may be dead cells or live cells.
- the cells may exist in a culture medium, buffer solution, or the like, or may be concentrated to remove the liquid, a lyophilized product thereof, or a frozen stock.
- the bacterial cell culture may contain bacterial secretions, metabolites, and the like.
- Cell cultures can contain peptides, proteins, sugars, enzymes, organic acids produced by bacteria, and media containing these (liquid media and solid media).
- the cell culture may be the supernatant after culturing bacteria.
- the culture supernatant can be obtained, for example, by removing bacteria from a liquid medium in which bacteria have been cultured, by centrifugation, filtration, or the like.
- NITE-BP-03198, NITE-BP-03199, NITE-BP-03200, NITE-BP-03201 and NITE-BP-03202 can be cultured according to a normal culture method for lactic acid bacteria.
- a typical culture method includes a method of culturing at a temperature of 30° C. using MRS (de Mann, Rogosa and Sharpe) liquid medium or MRS agar medium.
- the bacterial cell or bacterial cell culture extract is prepared so as not to lose the antibacterial activity against periodontal disease bacteria possessed by the lactic acid bacteria cell or bacterial cell culture. Extracts can be obtained, for example, by subjecting bacterial cells or cell cultures to ultrasonic disruption, bead grinding, freeze-thawing, chemical lysis, or the like. The extract may be obtained by salting-out, ultrafiltration, ion-exchange chromatography, liquid-phase extraction using an organic solvent, or the like, on the cells or cell culture. These treatments can be performed in combination as appropriate.
- the extract may contain bacterial cell fragments, nucleic acids, peptides, proteins, sugars and enzymes. In the present specification, bacterial cells, bacterial cell cultures, or extracts thereof are also referred to as "microbial cell preparations.”
- the oral composition may be an oral composition that is taken into the body through the oral cavity.
- the oral composition may be a food product and may be a non-human animal food or feed.
- the oral composition may be a composition that is used in the oral cavity and is discharged from the oral cavity after use.
- the oral composition may be a composition for extra-oral use.
- the composition for extraoral use may be, for example, a denture cleanser.
- the oral composition can be, for example, an oral care product.
- the oral composition preferably the oral composition, can contain additive components within a range that does not impair the effects of the present invention.
- Additives suitable for oral intake include solvents such as water, carbohydrates, proteins, lipids, vitamins, minerals, trace metals essential for living organisms (manganese sulfate, zinc sulfate, magnesium chloride, potassium carbonate, etc.), fragrances, and foods. sanitary or pharmaceutically acceptable carriers, food additives and the like.
- Additive components can be added as needed by appropriately selecting one or a combination of two or more.
- Carbohydrates include saccharides, processed starch (dextrin, soluble starch, British starch, oxidized starch, starch ester, starch ether, etc.), dietary fiber, and the like.
- Proteins include whole milk powder, skimmed milk powder, partially skimmed milk powder, casein, whey powder, whey protein, whey protein concentrate, whey protein isolate, ⁇ -casein, ⁇ -casein, ⁇ -casein, ⁇ -lactoglobulin, Animal and plant proteins such as ⁇ -lactalbumin, lactoferrin, soy protein, chicken egg protein, and meat protein, and their hydrolysates, as well as butter, milk minerals, cream, whey, non-protein nitrogen, sialic acid, and phosphorus Examples include lipids and various milk-derived components such as lactose.
- Lipids include animal oils such as lard, fish oil, fractionated oils thereof, hydrogenated oils thereof, transesterified oils thereof, palm oil, safflower oil, corn oil, rapeseed oil, coconut oil, Vegetable oils and fats such as these fractionated oils, these hydrogenated oils, and these interesterified oils are included.
- Vitamins include vitamin A, carotene, vitamin B group, vitamin C, vitamin D group, vitamin E, vitamin K group, vitamin P, vitamin Q, niacin, nicotinic acid, pantothenic acid, biotin, inositol, choline, and folic acid. etc.
- Minerals include calcium, potassium, magnesium, sodium, copper, iron, manganese, zinc, and selenium.
- the oral composition may be in an orally ingestible form such as solution, suspension, emulsion, powder, paste, semi-solid molding, or solid molding.
- Foods include, for example, milk, vegetable milk, milk beverages, soft drinks, fermented milk, lactic acid beverages, lactic beverages, infant formula, liquid milk, liquid diets, foods for the sick, frozen foods.
- fermented foods processed foods, confectionery, seasonings and other commercially available foods. More specific examples include yoghurt, cheese, ice cream, ice cream, chocolate, tablets, gummies, candies, jellies, gums, breads, biscuits, crackers, pizza crusts, and the like.
- the oral composition may be supplements, health foods, functional foods, foods for special dietary uses, foods with health claims, foods for specified health uses, foods with nutrient function claims, foods with function claims, quasi-drugs, cosmetics, and the like. , tablets, capsules, powders, granules, jelly and the like.
- the oral composition preferably the oral care product, can contain additive components within a range that does not impair the effects of the present invention.
- additive components include fluorine compounds, medicinal ingredients, abrasives, binders, thickening agents, surfactants, corrigents, preservatives, fragrances, coloring agents, pH adjusters, solvents, solubilizers, and bases. , detergents, adsorbents, and the like.
- the additive component can be appropriately selected according to the dosage form of the composition. Additive components can be added as needed by appropriately selecting one or a combination of two or more.
- fluorine compounds include sodium fluoride, potassium fluoride, ammonium fluoride, tin fluoride, amine fluoride, sodium monofluorophosphate, potassium monofluorophosphate, sodium silicon fluoride, and calcium silicon fluoride. Sodium fluoride or sodium monofluorophosphate is preferred. Fluorine compounds can inhibit caries.
- the fluorine compound is used in an amount such that the fluorine concentration in the composition is, for example, 1001 ppm to 3000 ppm, preferably 1001 ppm to 2000 ppm, more preferably 1001 ppm to 1500 ppm.
- medicinal ingredients bactericides, anti-inflammatory agents, blood circulation promoters, tartar deposition inhibitors, stain removers, hypersensitivity inhibitors, vitamins, crude drug extracts, plaque-degrading enzymes, etc. are added to the oral composition. can do.
- These medicinal ingredients are not particularly limited as long as they can be used for pharmaceuticals and the like.
- Bactericides include cationic fungicides such as cetylpyridinium chloride, benzalkonium chloride, benzethonium chloride, chlorhexidine hydrochloride, and chlorhexidine gluconate; amphoteric fungicides such as dodecyldiaminoethylglycine; ionic fungicides; and hinokitiol and the like.
- Anti-inflammatory agents include ⁇ -glycyrrhetinic acid, glycyrrhetinic acid, glycyrrhizic acid, diammonium glycyrrhizinate, disodium glycyrrhizinate, trisodium glycyrrhizinate, dipotassium glycyrrhizinate, monoammonium glycyrrhizinate, ⁇ -aminocaproic acid, azulene sulfonic acid.
- Examples of blood circulation promoting agents include sodium chloride.
- zeolite As a tartar deposition inhibitor, zeolite, disodium hydrogen phosphate, disodium dihydrogen pyrophosphate, sodium pyrophosphate, anhydrous sodium pyrophosphate, tetrasodium pyrophosphate (anhydrous), disodium monohydrogen phosphate, sodium hydrogen phosphate hydrate, disodium hydrogen phosphate (crystal), trisodium phosphate, sodium polyphosphate and the like.
- macrogol As a stain remover, macrogol (Macrogol 200, Macrogol 300, Macrogol 400, Macrogol 600, Macrogol 1000, Macrogol 1500, Macrogol 1540, Macrogol 4000, Macrogol 6000, Macrogol 20000, etc.) , sodium polyphosphate, polyvinylpyrrolidone, and the like.
- antihypersensitivity agents examples include potassium nitrate and aluminum lactate.
- Vitamin preparations include ascorbic acid, L-ascorbic acid, sodium ascorbate, sodium L-ascorbate, pyridoxine hydrochloride, DL- ⁇ -tocopherol acetate, tocopherol acetate, dl- ⁇ -tocopherol nicotinate, tocopherol nicotinate etc.
- abrasives examples include silicic anhydride, silica (crystalline silica or amorphous silica), silica gel, silica-based abrasives such as aluminosilicate, zeolite, calcium hydrogen phosphate anhydrate, and calcium hydrogen phosphate dihydrate. substances, calcium pyrophosphate, calcium carbonate, aluminum hydroxide, alumina, magnesium carbonate, magnesium phosphate tertiary, zirconium silicate, calcium phosphate tertiary, hydroxyapatite, calcium tetraphosphate, and synthetic resin abrasives.
- Binders include pullulan, gelatin, methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, sodium carboxymethylcellulose, carrageenan, sodium alginate, xanthan gum, sodium polyacrylate, gum arabic, guar gum, locust bean gum, polyvinyl alcohol, polyvinylpyrrolidone, and organic binders such as carboxyvinyl polymer, and inorganic binders such as thickening silicic anhydride and bentonite.
- thickening agents include polyhydric alcohols (more specifically, sorbitol, glycerin, concentrated glycerin, ethylene glycol, propylene glycol, 1,3-butylene glycol, propanediol (1,3-propanediol), polyethylene glycol, polypropylene glycol, xylitol, maltitol, lactitol, etc.), trehalose, sodium hyaluronate, hydrolyzed collagen, and the like.
- polyhydric alcohols more specifically, sorbitol, glycerin, concentrated glycerin, ethylene glycol, propylene glycol, 1,3-butylene glycol, propanediol (1,3-propanediol), polyethylene glycol, polypropylene glycol, xylitol, maltitol, lactitol, etc.
- trehalose sodium hyaluronate
- hydrolyzed collagen and the like.
- Surfactants include anionic surfactants such as N-acyl amino acid salts, ⁇ -olefin sulfonates, N-acyl sulfonates, alkyl sulfates (eg, sodium lauryl sulfate, etc.), sulfates of glycerin fatty acid esters. etc.
- Nonionic surfactants include polyoxyethylene alkyl ether, polyoxyethylene-polyoxypropylene block copolymer, polyoxyethylene hydrogenated castor oil, polyoxyethylene ether of glycerin ester, sucrose fatty acid ester, alkylolamide, glycerin.
- Amphoteric surfactants include alkyl betaine surfactants, amine oxide surfactants, and imidazolinium betaine surfactants. Specific examples of these include 2-alkyl-N-carboxymethyl-N-hydroxyethylimidazolinium betaine, lauryldimethylaminoacetic acid betaine, coconut oil alkylbetaine (coconut alkyldimethylaminoacetic acid betaine), stearyldimethylaminoacetic acid betaine. .
- flavoring agents include sodium L-glutamate, saccharin, sodium saccharin, disodium glycyrrhizinate, trisodium glycyrrhizinate, sucrose, glucose, fructose, lactose, honey, aspartame, stevia, sucralose, xylitol, inositol, and D-sorbitol.
- D-mannitol arabitol, raffinose, lactulose, lactitol, erythritol, reduced palatinose, palatinose, palatinit, acesulfame K, maltose, maltosyltrehalose, maltitol, neohesperidin dihydrochalcone, perillartine, p-methoxycinnamic aldehyde, thaumatin, etc. is mentioned.
- antiseptics examples include glycine, sodium benzoate, paraoxybenzoic acid esters such as methylparaben, ethylparaben, butylparaben, isopropylparaben, propylparaben, isobutylparaben, and benzylparaben; alcohols such as phenoxyethanol and ethanol; acid, benzoic acid, dehydroacetic acid, propionic acid and salts thereof, ethylenediaminetetraacetate, benzalkonium chloride, benzethonium chloride, cetylpyridinium chloride, and alkyldiaminoethylglycine hydrochloride.
- paraoxybenzoic acid esters such as methylparaben, ethylparaben, butylparaben, isopropylparaben, propylparaben, isobutylparaben, and benzylparaben
- alcohols such as phenoxyethanol and
- Flavors include, for example, L-menthol, peppermint, spearmint, fruit flavors, and peppermint oil. Perfumes also have the advantage of stimulating salivation.
- Coloring agents include safflower red pigment, gardenia yellow pigment, gardenia blue pigment, perilla pigment, monascus pigment, red cabbage pigment, carrot pigment, hibiscus pigment, cacao pigment, spirulina blue pigment, and natural pigment such as coumarind pigment, red Legal pigments such as No. 3, Red No. 104, Red No. 105, Red No. 106, Yellow No. 4, Yellow No. 5, Green No. 3, and Blue No. 1, riboflavin, sodium copper chlorophyllin, and titanium dioxide. .
- pH adjusters include formic acid, lactic acid, acetic acid, hydrochloric acid, sulfuric acid, nitric acid, citric acid, phosphoric acid, malic acid, gluconic acid, maleic acid, succinic acid, glutamic acid, pyrophosphoric acid, tartaric acid, sodium acetate hydroxide, hydroxide Acids, alkalis, and buffers such as potassium, sodium acetate, sodium carbonate, sodium citrate, sodium hydrogen citrate, phosphoric acid, sodium phosphate, sodium monohydrogen phosphate, and sodium dihydrogen phosphate potassium dihydrogen phosphate etc.
- solvents examples include water and lower alcohols such as ethanol and propanol.
- a solubilizer may be added to promote the dissolution of the above additives or medicinal ingredients in water.
- solubilizers include polyhydric alcohols such as propylene glycol, dipropylene glycol, butylene glycol, and polyethylene glycol.
- bases examples include sodium hydrogen carbonate.
- cleaning agents examples include sodium polyphosphate.
- adsorbents examples include ⁇ -cyclodextrin.
- Oral compositions include, for example, mouthwashes, dentifrices (toothpaste, liquid toothpaste, toothpaste, etc.), mouth fresheners, gums, lozenges, buccal tablets, gingival adhesive tape preparations, intraoral oral gel, oral ointment, oral spray, oral paste, oral paste, oral pill, oral tablet, oral powder, oral powder, oral liquid , intraoral suspensions, intraoral emulsions, intraoral granules, intraoral capsules, and denture cleaners.
- the oral composition is preferably a mouthwash or dentifrice.
- Oral compositions may be quasi-drugs, hygiene products or cosmetics.
- the manufacturing method of the oral composition is not particularly limited.
- the oral composition may be manufactured by any manufacturing method by which common oral compositions, oral care products, and the like are manufactured.
- a method for producing an oral composition may include a step of adding the cell preparation of the lactic acid bacterium to any step of a general oral composition, an oral care composition, or the like.
- the method for producing an oral composition may include, for example, a step of adding the cell preparation of lactic acid bacteria to the oral composition, oral care product and the like produced.
- the composition for oral cavity may be the bacterial cell preparation itself of the above-mentioned lactic acid bacteria.
- the oral composition may contain liquids, spreading agents, and the like to facilitate the attachment, absorption, or mixing of the lactic acid bacteria cell preparation with the oral composition, oral care products, and the like.
- the amount of the lactic acid bacteria cell preparation contained in the oral cavity composition is not particularly limited as long as it exhibits an antibacterial activity against periodontal disease bacteria.
- the total amount of the cell preparation of lactic acid bacteria in the oral composition may be, for example, 1 ⁇ 10 3 to 1 ⁇ 10 12 cfu (colony forming units)/g. 12 cfu/g, or 1 ⁇ 10 5 to 1 ⁇ 10 12 cfu/g.
- the colony-forming unit can be determined by an agar plate culture method.
- the total amount (content ratio) of the bacterial cell preparation of lactic acid bacteria in the oral composition is 0.0001% by mass to 30% by mass, preferably 0.001% by mass to 10% by mass relative to the weight of the oral composition. %.
- the total concentration of the lactic acid bacteria cell preparation in the oral composition may be 0.1 to 100,000 ppm, may be 1 to 100,000 ppm, or may be 10 to 100,000 ppm. may The total amount can be weighed with a balance or the like.
- the oral composition can be applied to animals.
- the animal may be a human or non-human animal.
- Animals include mammals. Mammals may include Rodentia, Lagomorpha, Carnivora, Cetatodactyla, Perissodactyla, Primate. More specifically, the above mammals include mice, rats, hamsters, guinea pigs, hedgehogs, ferrets, rabbits, dogs, cats, cows, pigs, goats, horses, sheep, monkeys, orangutans, chimpanzees and the like. Animals may be pets, farm animals or laboratory animals.
- One embodiment of the present invention is the use of Lactobacillus plantarum cells or cell cultures or extracts thereof in the production of oral compositions.
- the oral composition according to the present invention may be a preventive or therapeutic composition for oral diseases.
- treatment includes alleviation of symptoms, amelioration of symptoms, and complete cure.
- the prophylactic or therapeutic composition may be pharmaceuticals or veterinary drugs, quasi-drugs, cosmetics, and the like.
- Lactobacillus plantarum exhibits antimicrobial activity against causative bacteria of oral diseases
- Lactobacillus plantarum can be used to prevent or treat oral diseases.
- Oral diseases include periodontal diseases such as gingivitis and periodontitis; dental caries; oral candidiasis; mucositis; glossitis; Bacteria that cause periodontal disease include Porphyromonas gingivalis (hereinafter also referred to as "Pg bacteria”) and Tannerella forsythia (hereinafter also referred to as Tf bacteria). ), Treponema denticola (hereinafter also referred to as "T.d.
- Caries-causing bacteria include Streptococcus mutans, Streptococcus sobrinus, and the like.
- Candida fungi include Candida albicans, Candida glabrata, Candida tropicalis, and the like.
- compositions containing a bacterial cell preparation of Lactobacillus plantarum are effective in preventing or treating oral diseases.
- compositions containing bacterial cell preparations of Lactobacillus plantarum are more effective than antibiotics (minocycline, etc.) and chemical fungicides (cetylpyridinium chloride (CPC), isopropylmethylphenol (IPMP), etc.) on oral flora. Less is. For this reason, compositions containing a cell preparation of Lactobacillus plantarum are less likely to unbalance the oral microflora. Cell preparations of Lactobacillus plantarum can also inhibit the growth of bacteria that promote plaque formation. Bacteria that promote plaque formation include, for example, Streptococcus gordonii (hereinafter also referred to as “Gordonii”).
- the preventive or therapeutic composition may or may not contain other antibacterial agents and antibiotics against causative bacteria of oral diseases.
- the dosage form and manufacturing method of the preventive or therapeutic composition may be the same as the dosage form and manufacturing method of the composition described above.
- the content of the bacterial cell preparation of Lactobacillus plantarum in the preventive or therapeutic composition is not particularly limited as long as it exhibits antibacterial activity against periodontal disease bacteria, and is the same range as the content in the oral composition. can be
- One embodiment of the present invention is the use of Lactobacillus plantarum cells or cell cultures or extracts thereof in the manufacture of compositions for the prevention or treatment of oral diseases.
- a method for preventing or treating oral diseases includes applying Lactobacillus plantarum cells or cell cultures or extracts thereof to the oral cavity of an animal.
- the animal may be a human or non-human animal.
- Oral diseases include periodontal diseases such as gingivitis and periodontitis; dental caries; oral candidiasis; mucositis; glossitis;
- the bacterial cell preparation of Lactobacillus plantarum may be orally ingested, or may be excreted out of the oral cavity after being used in the oral cavity.
- Cells or cell cultures of Lactobacillus plantarum or extracts thereof may be supplied as the intraoral composition.
- One embodiment of the present invention is the use of Lactobacillus plantarum cells or cell cultures or extracts thereof for the prevention or treatment of oral diseases.
- a growth inhibitor or fungicide for periodontal disease-causing bacteria contains Lactobacillus plantarum cells, cell cultures, or extracts thereof.
- Periodontal disease-causing bacteria include, for example, at least one selected from Porphyromonas gingivalis, Tannerella forsythia, and Treponema denticola.
- Lactobacillus plantarum cells, cell cultures, or extracts thereof can inhibit the growth of or kill periodontal disease-causing bacteria, and particularly have antibacterial activity against all of the above three causative bacteria.
- the antiproliferative agent or bactericidal agent may be in the same form as the oral composition.
- Antiproliferative agents or antiseptics may or may not include other antibacterial agents and antibiotics against causative agents of oral disease.
- the content of the lactic acid bacteria cell preparation contained in the growth inhibitor or bactericide is not particularly limited, but may be, for example, 1 ⁇ 10 3 to 1 ⁇ 10 12 cfu/mL, or 1 ⁇ 10 5 to 1 ⁇ 10 cfu/mL. It may be x10 12 cfu/mL, or may be from 1 x 10 7 to 1 x 10 12 cfu/mL.
- the colony-forming unit can be determined by an agar plate culture method.
- the total concentration of the lactic acid bacteria cell preparation contained in the growth inhibitor or disinfectant is not particularly limited, and may be 0.1 to 100,000 ppm, or 1 to 100,000 ppm. , from 10 to 100,000 ppm. The total concentration can be weighed with a balance or the like.
- a method for inhibiting or sterilizing the growth of periodontal disease-causing bacteria comprises contacting Lactobacillus plantarum bacteria or bacterial cell cultures or extracts thereof with periodontal disease-causing bacteria. Including.
- the method of contacting the bacterial cell preparation of Lactobacillus plantarum with the causative bacteria of periodontal disease is not particularly limited. may be added, an object in which periodontal disease-causing bacteria are present may be immersed in a liquid containing a bacterial cell preparation of Lactobacillus plantarum, and a host infected with periodontal disease-causing bacteria may be lacto Compositions containing the bacterial cell preparation of Bacillus plantarum may be administered orally.
- the bacterial cell preparation of Lactobacillus plantarum may be supplied in the form of a periodontal disease-causing bacteria growth inhibitor or bactericide.
- One embodiment of the present invention is the use of Lactobacillus plantarum cells or cell cultures or extracts thereof in the production of growth inhibitors or fungicides for periodontal disease-causing bacteria.
- One embodiment of the present invention is the use of Lactobacillus plantarum cells or cell cultures or extracts thereof for growth inhibition or sterilization of periodontal disease-causing bacteria.
- Isolate A was identified by 16S rRNA gene analysis, morphological observation, and physiological and biochemical characterization tests.
- 16S rRNA gene analysis Genomic DNA was extracted from the isolate A, and the resulting genomic DNA was used as a template for cloning forward primer 9F and cloning reverse primer 1510R (Yoshiyoshi Nakagawa et al.: Genetic analysis method of 16S rRNA gene.
- PCR amplification of the 16S rRNA gene was performed using a nucleotide sequencing method, Actinomycetes Society of Japan, Classification and Identification of Actinomycetes, 88-117 pp. Japan Society Office, 2001).
- PCR amplification was performed using Tks Gflex DNA polymerase (manufactured by Takara Bio Inc.), and the amplified product after PCR was purified.
- a cycle sequencing reaction was performed using the purified amplified product after PCR.
- the cycle sequencing reaction was performed using BigDye Terminator v3.1 Cycle Sequencing Kit.
- the resulting reaction solution was purified, and the purified solution was subjected to DNA sequence analysis (3130xl DNA Analyzer) to determine the base sequence of the 16S rRNA gene of the template DNA extracted from isolate A.
- Sequence analysis primers include 9F, 515F, 1099F, 536R, 926R, and 1510R (Yoshiyoshi Nakagawa et al.: Gene analysis method 16S rRNA gene sequencing method, Actinomycetes Society of Japan, Classification and Identification of Actinomycetes, 88 -117 pp. Japan Society Administrative Center, 2001) was used.
- the base sequence of the 16S rRNA gene of isolate A was identified as a microorganism identification database DB-BA15.0 (manufactured by Techno Suruga Lab), an international base sequence database A BLAST homology search was performed against (DDBJ/ENA(EMBL)/GenBank).
- the nucleotide sequence of the 16S rRNA gene of isolate A has 99.87% identity to the nucleotide sequence of the 16S rRNA gene of Lactobacillus pentosus (JCM1558), Lactobacillus plantarum subsp.
- isolate A formed circular colonies.
- isolate A was positive for Gram staining.
- Tables 1 and 2 show the results of physiological/biochemical property tests and fermentability tests of isolate A. Isolate A was a non-motile Gram-positive bacillus, did not form spores, was negative in catalase and oxidase reactions, and fermented glucose. These properties were consistent with those of the genus Lactobacillus, for which the possibility of attribution was shown as a result of 16S rDNA partial nucleotide sequence analysis.
- isolate A fermented galactose, fructose, melezitose, etc., but did not ferment glycerol, D-xylose, etc.
- Isolate A showed no arginine dihydrolase activity and grew at 15°C. These properties were attributed to L. cerevisiae, whose attribution was suggested as a result of 16S rDNA partial nucleotide sequence analysis.
- pentosus and L. Among L. plantarum, L. plantarum shows no fermentation of glycerol and D-xylose. Unlike L. pentosus, L. It matched the properties of plantarum. Therefore, isolate A was found to be a novel isolate belonging to Lactobacillus plantarum. The isolate A was internationally deposited as NITE BP-03198.
- Isolate B was isolated by the same method as Experiment 1, except that Lembu was used as the isolation source. Identification of isolate B was performed by the same method as in Experiment 1.
- the base sequence of the 16S rRNA gene of isolate B has 100.0% identity to the base sequence of the 16S rRNA gene of Lactobacillus pentosus (JCM1558), Lactobacillus plantarum subsp. It showed 100.0% identity to the nucleotide sequence of the 16S rRNA gene of Lactobacillus (JCM1149) and 99.80% identity to the nucleotide sequence of the 16S rRNA gene of Lactobacillus paraplantarum (DSM10667).
- isolate B formed circular colonies. As shown in FIG. 2B, isolate B was positive for Gram staining. Tables 3 and 4 show the results of physiological and biochemical property tests and fermentability tests of isolate B. Isolate B was a non-motile Gram-positive bacillus, did not form spores, was negative in catalase and oxidase reactions, and fermented glucose. These properties were consistent with those of the genus Lactobacillus, for which the possibility of attribution was shown as a result of 16S rDNA partial nucleotide sequence analysis.
- isolate B fermented galactose, fructose, ⁇ -methyl-D-mannoside and melezitose, etc., but did not ferment glycerol, D-xylose, etc.
- Isolate B showed no arginine dihydrolase activity and grew at 15°C. These properties were attributed to L. cerevisiae, whose attribution was suggested as a result of 16S rDNA partial nucleotide sequence analysis.
- pentosus and L Among L. plantarum, L. plantarum shows no fermentation of glycerol and D-xylose. Unlike L. pentosus, L. It matched the properties of plantarum. Therefore, isolate B was found to be a novel isolate belonging to Lactobacillus plantarum. Isolate B was internationally deposited as NITE BP-03199.
- the base sequence of the 16S rRNA gene of isolate C has 99.87% identity to the base sequence of the 16S rRNA gene of Lactobacillus pentosus (JCM1558), Lactobacillus plantarum subsp. It showed 99.87% identity to the nucleotide sequence of the 16S rRNA gene of Lactobacillus (JCM1149) and 99.66% identity to the nucleotide sequence of the 16S rRNA gene of Lactobacillus paraplantarum (DSM10667). However, there was no microorganism with a 16S rRNA gene that completely matched the base sequence of the isolate C 16S rRNA gene.
- isolate C formed circular colonies. As shown in FIG. 3B, isolate C was positive for Gram staining. Tables 5 and 6 show the results of physiological and biochemical property tests and fermentability tests of isolate C. Isolate C was a non-motile Gram-positive bacillus, did not form spores, was negative in catalase and oxidase reactions, and fermented glucose. These properties were consistent with those of the genus Lactobacillus, for which the possibility of attribution was shown as a result of 16S rDNA partial nucleotide sequence analysis.
- isolate C fermented galactose, fructose, ⁇ -methyl-D-mannoside and melezitose, etc., but did not ferment glycerol, D-xylose, etc.
- Isolate C showed no arginine dihydrolase activity and grew at 15°C. These properties were shown to be closely related as a result of 16S rDNA partial nucleotide sequence analysis.
- pentosus and L Among L. plantarum, L. plantarum shows no fermentation of glycerol and D-xylose. Unlike L. pentosus, L. It matched the properties of plantarum. Therefore, isolate C was found to be a novel isolate belonging to Lactobacillus plantarum. Isolate C was internationally deposited as NITE BP-03200.
- the base sequence of the 16S rRNA gene of isolate D has 99.93% identity to the base sequence of the 16S rRNA gene of Lactobacillus pentosus (JCM1558), Lactobacillus plantarum subsp. It showed 99.93% identity to the nucleotide sequence of the 16S rRNA gene of Lactobacillus (JCM1149) and 99.73% identity to the nucleotide sequence of the 16S rRNA gene of Lactobacillus paraplantarum (DSM10667). However, no microorganism with a 16S rRNA gene that completely matches the base sequence of the 16S rRNA gene of isolate D was found.
- isolate D formed circular colonies.
- isolate D was positive for Gram staining.
- Tables 5 and 6 show the results of physiological/biochemical property tests and fermentability tests of isolate D. Isolate D was a non-motile Gram-positive bacillus, did not form spores, was negative in catalase and oxidase reactions, and fermented glucose. These properties were consistent with those of the genus Lactobacillus, for which the possibility of attribution was shown as a result of 16S rDNA partial nucleotide sequence analysis.
- isolate D fermented galactose, fructose and melezitose, etc., but did not ferment glycerol, D-xylose, etc.
- Isolate D showed no arginine dihydrolase activity and grew at 15°C. These properties were attributed to L. cerevisiae, whose attribution was suggested as a result of 16S rDNA partial nucleotide sequence analysis.
- pentosus and L. Among L. plantarum, L. plantarum shows no fermentation of glycerol and D-xylose. Unlike L. pentosus, L. It matched the properties of plantarum. Therefore, isolate D was found to be a novel isolate belonging to Lactobacillus plantarum. Isolate D was internationally deposited as NITE BP-03201.
- Isolate E was isolated by the same method as in Experiment 1, except that Pinus chinensis was used as the isolation source. Identification of isolate E was performed by the same method as in Experiment 1.
- the nucleotide sequence of the 16S rRNA gene of isolate E has 99.93% identity to the nucleotide sequence of the 16S rRNA gene of Lactobacillus pentosus (JCM1558), Lactobacillus plantarum subsp. It showed 99.93% identity to the nucleotide sequence of the 16S rRNA gene of Lactobacillus (JCM1149) and 99.73% identity to the nucleotide sequence of the 16S rRNA gene of Lactobacillus paraplantarum (DSM10667). However, no microorganism with a 16S rRNA gene that completely matches the base sequence of the isolate E 16S rRNA gene was found.
- isolate E formed circular colonies. As shown in FIG. 5B, isolate E was positive for Gram staining. Tables 9 and 10 show the results of physiological and biochemical property tests and fermentability tests of isolate E. Isolate E was a non-motile Gram-positive bacillus, did not form spores, was negative in catalase and oxidase reactions, and fermented glucose. These properties were consistent with those of the genus Lactobacillus, for which the possibility of attribution was shown as a result of 16S rDNA partial nucleotide sequence analysis.
- isolate E fermented galactose, fructose, ⁇ -methyl-D-mannoside and melezitose, etc., but did not ferment glycerol, D-xylose, etc.
- Isolate E showed no arginine dihydrolase activity and grew at 15°C. These properties were attributed to L. cerevisiae, whose attribution was suggested as a result of 16S rDNA partial nucleotide sequence analysis.
- pentosus and L Among L. plantarum, L. plantarum shows no fermentation of glycerol and D-xylose. Unlike L. pentosus, L. It matched the properties of plantarum. Therefore, isolate E was found to be a novel isolate belonging to Lactobacillus plantarum. The isolate E was internationally deposited as NITE BP-03202.
- periodontal disease-causing bacteria Pg, Tf and Td
- the causative bacteria of periodontal disease were suspended in GAM broth, and McFarland No. 0.5 (approximately 1 ⁇ 10 8 to 2 ⁇ 10 8 cfu/mL). This was further diluted 10-fold to obtain a periodontal disease-causing bacterial solution 11 (about 1 ⁇ 10 7 to 2 ⁇ 10 7 cfu/mL).
- 100 ⁇ L of periodontal disease bacterium liquid 11 was dropped on an agar medium 12 for measurement, and was evenly applied with a Conlarge stick.
- the bacterial cell preparation of Lactobacillus plantarum is obtained by culturing any of NITE BP-03198, NITE BP-03199, NITE BP-03200, NITE BP-03201 and NITE BP-03202 in MRS Broth at a temperature of 30 ° C. Then, the culture supernatant (cell culture) obtained by sedimenting the cells by centrifugation was used. P. g. fungus, T. f. fungi and T. d. The results of antibacterial activity against fungi are shown in Tables 12, 13 and 14, respectively. A medium for lactic acid bacteria (MRS Broth) was used as a negative control.
- Sensidisc “MEPM” manufactured by Nippon Becton Dickinson
- Sensidisc “LVFX” manufactured by Nippon Becton Dickinson
- ATCC-11454 is a nisin-A producing lactic acid bacterium (Lactococcus subsp. lactis). The nisin A-producing strain was cultured in the same manner as Lactobacillus plantarum, and the culture supernatant was prepared.
- NITE BP-03198, NITE BP-03199, NITE BP-03200, NITE BP-03201 and NITE BP-03202 are P. g. fungus, T. f. fungi and T. d.
- Both bacterial cell cultures of Lactobacillus plantarum are P. g. fungus, T. f. fungi and T. d. It was shown that the growth of bacteria can be suppressed.
- the culture supernatant of the nisin A-producing strain was T. cerevisiae. d. Although it inhibited the growth of P. g. fungi and T. f. It was not possible to suppress the growth of bacteria.
- Experiment 7 was performed in the same manner as Experiment 6, except that Goldoni bacteria were used as bacteria for verifying antibacterial activity.
- Gordonii was pre-cultured according to the medium and culture conditions described in Table 15.
- Gordonii bacteria were suspended in GAM broth and added to McFarland No. 0.5 (approximately 1 ⁇ 10 8 to 2 ⁇ 10 8 cfu/mL). This was further diluted 10-fold to obtain Gordonii fungus solution 11 (about 1 ⁇ 10 7 to 2 ⁇ 10 7 cfu/mL). 100 ⁇ L of the Gordonii fungus solution 11 was dropped on the agar medium 12 for measurement, and was evenly applied with a Conlarge stick.
- Experiment 8 was carried out in the same manner as Experiment 6, except that B. salivarius was used as the bacterium for verifying the antibacterial activity.
- B. salivarius was pre-cultured according to the medium and culture conditions described in Table 17.
- Salivarius was suspended in GAM broth and plated with McFarland No. 0.5 (approximately 1 ⁇ 10 8 to 2 ⁇ 10 8 cfu/mL). This was further diluted 10-fold to obtain Salivarius bacterial solution 11 (approximately 1 ⁇ 10 7 to 2 ⁇ 10 7 cfu/mL). 100 ⁇ L of the bacterial solution 11 of Salivarius salivarius was dropped on the agar medium 12 for measurement, and was evenly applied with a Conlarge stick.
- NITE BP-03198, NITE BP-03199, NITE BP-03200, NITE BP-03201 and NITE BP-03202 caused growth inhibition circles to form in the growth medium of Salivarius. It was shown that the bacterial cell culture of Lactobacillus plantarum has little effect on oral flora. On the other hand, tetracycline also suppressed the growth of oral flora.
- Bacteria that cause periodontal disease, bacteria that promote plaque formation, or fungal fluids of oral bacteria 12. Agar medium for measurement, 13. Lactobacillus plantarum bacterial cell preparation, 14. Growth inhibition circle.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Provided is an oral composition that includes Lactobacillus plantarum cells or cell cultures or an extract of these. The Lactobacillus plantarum is ideally at least one type selected from NITE-BP-03198, NITE-BP-03199, NITE-BP-03200, NITE-BP-03201, and NITE-BP-03202. Also provided is a prophylactic or therapeutic method for oral cavity diseases, that includes the application of Lactobacillus plantarum cells or cell cultures or an extract of these to the oral cavity of animals.
Description
本発明は、口腔用組成物、および口腔内疾患の予防または治療方法に関する。
The present invention relates to an oral composition and a method for preventing or treating oral diseases.
歯周病は、歯周病菌等の病原微生物によって引き起こされ、人類の多くが罹患する感染症である。歯周病を抑制するために、病原菌に対する抗菌活性を有する成分を含む組成物が開発されている。国際公開第2011/007584号(特許文献1)には、ラクトバチルス・ラムノーサスKO3株、ラクトバチルス・カゼイYU3株およびラクトバチルス・パラカゼイYU4株から選ばれる1種以上の細菌の菌体もしくは菌体培養物等を有効成分する口腔内疾患の予防または治療剤が開示されている。国際公開第2012/108518号(特許文献2)には、ラクトバチルス・ラムノーサスKO1株およびラクトバチルス・ラムノーサスKO3株から産生されるKog1またはKog3を含む口腔内疾患の予防または治療用組成物が開示されている。
Periodontal disease is caused by pathogenic microorganisms such as periodontal disease bacteria, and is an infectious disease that affects many humans. Compositions containing ingredients with antibacterial activity against pathogenic bacteria have been developed to control periodontal disease. In International Publication No. 2011/007584 (Patent Document 1), one or more bacterial cells or bacterial cell cultures selected from Lactobacillus rhamnosus KO3 strain, Lactobacillus casei YU3 strain and Lactobacillus paracasei YU4 strain A prophylactic or therapeutic agent for oral diseases is disclosed, which contains a substance, etc. as an active ingredient. International Publication No. 2012/108518 (Patent Document 2) discloses a composition for preventing or treating oral diseases containing Kog1 or Kog3 produced from Lactobacillus rhamnosus KO1 strain and Lactobacillus rhamnosus KO3 strain. ing.
中国特許出願公開第108685716号明細書(特許文献3)には、ナイシンを含む練り歯磨きが開示されている。中国特許出願公開第105326656号明細書(特許文献4)には、ナイシンおよびポリリジンを含む口腔用抗菌組成物が開示されている。独国特許出願公開第102011116325号明細書(特許文献5)には、ラクトバチルス・クリスパタス、ラクトバチルス・ガセリおよびラクトバチルス・アシドフィルスに属する細菌の菌体またはその一部を含む口腔ケア用の組成物が開示されている。
Chinese Patent Application Publication No. 108685716 (Patent Document 3) discloses a toothpaste containing nisin. Chinese Patent Application Publication No. 105326656 (Patent Document 4) discloses an oral antibacterial composition comprising nisin and polylysine. German Patent Application Publication No. 102011116325 (Patent Document 5) discloses a composition for oral care comprising cells of bacteria belonging to Lactobacillus crispatus, Lactobacillus gasseri and Lactobacillus acidophilus or parts thereof. is disclosed.
本発明は、口腔内疾患を抑制し得る新規組成物を提供することを目的とする。
An object of the present invention is to provide a novel composition capable of suppressing oral diseases.
本発明は、以下に例示する項目に関する。
[1] ラクトバチルス・プランタラムの菌体もしくは菌体培養物またはこれらの抽出物を含む口腔用組成物。
[2] 食品である、[1]に記載の組成物。
[3] 前記食品は発酵食品である、[2]に記載の組成物。
[4] 洗口剤または歯磨剤である、[1]に記載の組成物。
[5] フッ素化合物をさらに含む、[1]または[4]に記載の組成物。
[6] 前記ラクトバチルス・プランタラムは、NITE-BP-03198、NITE-BP-03199、NITE-BP-03200、NITE-BP-03201およびNITE-BP-03202から選択される少なくとも1つである、[1]~[5]のいずれかに記載の組成物。
[7] 口腔内疾患の予防または治療用組成物である、[1]~[6]のいずれかに記載の組成物。
[8] 前記口腔内疾患は歯周病である、[7]に記載の組成物。
[9] ラクトバチルス・プランタラムの菌体もしくは菌体培養物またはこれらの抽出物を動物の口腔に適用することを含む、口腔内疾患の予防または治療方法。
[10] 前記口腔内疾患は歯周病である、[9]に記載の方法。
[11] ラクトバチルス・プランタラムの菌体もしくは菌体培養物またはこれらの抽出物を含む、歯周病の原因菌に対する増殖抑制剤または殺菌剤。
[12] 前記歯周病の原因菌は、ポルフィロモナス・ジンジバリス、タンネレラ・フォーサイシアおよびトレポネーマ・デンティコーラから選択される少なくとも1つを含む、[11]に記載の増殖抑制剤または殺菌剤。
[13] ラクトバチルス・プランタラムの菌体もしくは菌体培養物またはこれらの抽出物を歯周病の原因菌に接触させることを含む、歯周病菌の増殖抑制または殺菌方法。 The present invention relates to items exemplified below.
[1] An oral composition containing Lactobacillus plantarum cells, cell cultures, or extracts thereof.
[2] The composition according to [1], which is a food.
[3] The composition according to [2], wherein the food is a fermented food.
[4] The composition of [1], which is a mouthwash or dentifrice.
[5] The composition according to [1] or [4], further comprising a fluorine compound.
[6] The Lactobacillus plantarum is at least one selected from NITE-BP-03198, NITE-BP-03199, NITE-BP-03200, NITE-BP-03201 and NITE-BP-03202, The composition according to any one of [1] to [5].
[7] The composition according to any one of [1] to [6], which is a composition for preventing or treating oral diseases.
[8] The composition of [7], wherein the oral disease is periodontal disease.
[9] A method for preventing or treating oral diseases, which comprises applying Lactobacillus plantarum cells, cell cultures, or extracts thereof to the oral cavity of an animal.
[10] The method of [9], wherein the oral disease is periodontal disease.
[11] A growth inhibitor or bactericidal agent for periodontal disease-causing bacteria, containing Lactobacillus plantarum cells, cell cultures, or extracts thereof.
[12] The growth inhibitor or fungicide according to [11], wherein the periodontal disease-causing bacteria include at least one selected from Porphyromonas gingivalis, Tannerella forsythia, and Treponema denticola.
[13] A method for inhibiting the growth of or sterilizing periodontal disease bacteria, which comprises contacting Lactobacillus plantarum cells, cell cultures, or extracts thereof with periodontal disease-causing bacteria.
[1] ラクトバチルス・プランタラムの菌体もしくは菌体培養物またはこれらの抽出物を含む口腔用組成物。
[2] 食品である、[1]に記載の組成物。
[3] 前記食品は発酵食品である、[2]に記載の組成物。
[4] 洗口剤または歯磨剤である、[1]に記載の組成物。
[5] フッ素化合物をさらに含む、[1]または[4]に記載の組成物。
[6] 前記ラクトバチルス・プランタラムは、NITE-BP-03198、NITE-BP-03199、NITE-BP-03200、NITE-BP-03201およびNITE-BP-03202から選択される少なくとも1つである、[1]~[5]のいずれかに記載の組成物。
[7] 口腔内疾患の予防または治療用組成物である、[1]~[6]のいずれかに記載の組成物。
[8] 前記口腔内疾患は歯周病である、[7]に記載の組成物。
[9] ラクトバチルス・プランタラムの菌体もしくは菌体培養物またはこれらの抽出物を動物の口腔に適用することを含む、口腔内疾患の予防または治療方法。
[10] 前記口腔内疾患は歯周病である、[9]に記載の方法。
[11] ラクトバチルス・プランタラムの菌体もしくは菌体培養物またはこれらの抽出物を含む、歯周病の原因菌に対する増殖抑制剤または殺菌剤。
[12] 前記歯周病の原因菌は、ポルフィロモナス・ジンジバリス、タンネレラ・フォーサイシアおよびトレポネーマ・デンティコーラから選択される少なくとも1つを含む、[11]に記載の増殖抑制剤または殺菌剤。
[13] ラクトバチルス・プランタラムの菌体もしくは菌体培養物またはこれらの抽出物を歯周病の原因菌に接触させることを含む、歯周病菌の増殖抑制または殺菌方法。 The present invention relates to items exemplified below.
[1] An oral composition containing Lactobacillus plantarum cells, cell cultures, or extracts thereof.
[2] The composition according to [1], which is a food.
[3] The composition according to [2], wherein the food is a fermented food.
[4] The composition of [1], which is a mouthwash or dentifrice.
[5] The composition according to [1] or [4], further comprising a fluorine compound.
[6] The Lactobacillus plantarum is at least one selected from NITE-BP-03198, NITE-BP-03199, NITE-BP-03200, NITE-BP-03201 and NITE-BP-03202, The composition according to any one of [1] to [5].
[7] The composition according to any one of [1] to [6], which is a composition for preventing or treating oral diseases.
[8] The composition of [7], wherein the oral disease is periodontal disease.
[9] A method for preventing or treating oral diseases, which comprises applying Lactobacillus plantarum cells, cell cultures, or extracts thereof to the oral cavity of an animal.
[10] The method of [9], wherein the oral disease is periodontal disease.
[11] A growth inhibitor or bactericidal agent for periodontal disease-causing bacteria, containing Lactobacillus plantarum cells, cell cultures, or extracts thereof.
[12] The growth inhibitor or fungicide according to [11], wherein the periodontal disease-causing bacteria include at least one selected from Porphyromonas gingivalis, Tannerella forsythia, and Treponema denticola.
[13] A method for inhibiting the growth of or sterilizing periodontal disease bacteria, which comprises contacting Lactobacillus plantarum cells, cell cultures, or extracts thereof with periodontal disease-causing bacteria.
本発明によれば、口腔内疾患を抑制し得る組成物を提供することができる。
According to the present invention, it is possible to provide a composition capable of suppressing oral diseases.
以下、本発明を実施するための形態について詳細に説明する。なお、本発明は、以下の実施形態に限定されるものではない。本明細書において「A~B」という形式の表記は、範囲の上限下限(すなわちA以上B以下)を意味し、Aにおいて単位の記載がなく、Bにおいてのみ単位が記載されている場合、Aの単位とBの単位とは同じである。
Hereinafter, the embodiments for carrying out the present invention will be described in detail. In addition, this invention is not limited to the following embodiment. In this specification, the notation of the form "A to B" means the upper and lower limits of the range (that is, from A to B). and the unit of B are the same.
[口腔用組成物]
本発明の一実施形態に係る口腔用組成物は、ラクトバチルス・プランタラム(Lactobacillus plantarum)の菌体もしくは菌体培養物またはこれらの抽出物を含む。本発明に係る組成物は、歯周病菌に対する抗菌活性を有する。 [Composition for oral cavity]
An oral composition according to one embodiment of the present invention comprises cells or cell cultures of Lactobacillus plantarum or extracts thereof. The composition according to the present invention has antibacterial activity against periodontal bacteria.
本発明の一実施形態に係る口腔用組成物は、ラクトバチルス・プランタラム(Lactobacillus plantarum)の菌体もしくは菌体培養物またはこれらの抽出物を含む。本発明に係る組成物は、歯周病菌に対する抗菌活性を有する。 [Composition for oral cavity]
An oral composition according to one embodiment of the present invention comprises cells or cell cultures of Lactobacillus plantarum or extracts thereof. The composition according to the present invention has antibacterial activity against periodontal bacteria.
ラクトバチルス・プランタラムは、好ましくはNITE-BP-03198、NITE-BP-03199、NITE-BP-03200、NITE-BP-03201およびNITE-BP-03202から選択される少なくとも1つである。NITE-BP-03198、NITE-BP-03199、NITE-BP-03200、NITE-BP-03201およびNITE-BP-03202は、それぞれ受託番号NITE BP-03198(原寄託日:2020年4月9日)、受託番号NITE BP-03199(原寄託日:2020年4月9日)、受託番号NITE BP-03200(原寄託日:2020年4月9日)、受託番号NITE BP-03201(原寄託日:2020年4月9日)、受託番号NITE BP-03202(原寄託日:2020年4月9日)として、独立行政法人製品評価技術基盤機構特許微生物寄託センター(NPMD、住所:〒292-0818 千葉県木更津市かずさ鎌足2-5-8 122号室)にブダペスト条約に基づいて国際寄託されている細菌である。上記細菌は、いずれも乳酸菌の一種であるラクトバチルス・プランタラム(Lactobacillus plantarum)に属する細菌である。上記細菌の菌学的性質については、後述する表1~表10および図1~図5に示す。
Lactobacillus plantarum is preferably at least one selected from NITE-BP-03198, NITE-BP-03199, NITE-BP-03200, NITE-BP-03201 and NITE-BP-03202. NITE-BP-03198, NITE-BP-03199, NITE-BP-03200, NITE-BP-03201 and NITE-BP-03202 are respectively accession number NITE BP-03198 (original deposit date: April 9, 2020) , Accession No. NITE BP-03199 (Original Deposit Date: April 9, 2020), Accession No. NITE BP-03200 (Original Deposit Date: April 9, 2020), Accession No. NITE BP-03201 (Original Deposit Date: April 9, 2020), under the accession number NITE BP-03202 (original deposit date: April 9, 2020), National Institute of Technology and Evaluation Patent Microorganisms Depositary Center (NPMD, Address: 292-0818 Chiba It is a bacterium that has been internationally deposited under the Budapest Treaty at Room 122, 2-5-8 Kazusa Kamatari, Kisarazu City, Prefecture. All of the above bacteria belong to Lactobacillus plantarum, which is a kind of lactic acid bacteria. The mycological properties of the bacteria are shown in Tables 1 to 10 and FIGS. 1 to 5, which will be described later.
NITE-BP-03198は発酵食品中、NITE-BP-03199、NITE-BP-03200、NITE-BP-03201およびNITE-BP-03202は、自然環境中に存在するため、人への安全性も高いと考えられる。上記乳酸菌は、単離された細菌であってよい。
Since NITE-BP-03198 exists in fermented foods, and NITE-BP-03199, NITE-BP-03200, NITE-BP-03201 and NITE-BP-03202 exist in the natural environment, they are highly safe to humans. it is conceivable that. The lactic acid bacteria may be isolated bacteria.
本発明の一実施形態に係る口腔用組成物は、NITE-BP-03198、NITE-BP-03199、NITE-BP-03200、NITE-BP-03201およびNITE-BP-03202から選択される少なくとも1種の細菌の菌体もしくは菌体培養物またはこれらの抽出物を含む。菌体は、発酵食品中または環境中から単離されたものであってもよく、培養されたものであってもよい。菌体は死菌であっても生菌であってもよい。菌体は培養液、緩衝液等に存在しているものであってもよく、これらを濃縮して液体を除いたものまたはその凍結乾燥物であってもよく、凍結ストックであってもよい。
The oral composition according to one embodiment of the present invention is at least one selected from NITE-BP-03198, NITE-BP-03199, NITE-BP-03200, NITE-BP-03201 and NITE-BP-03202 bacteria or bacterial cell cultures or extracts thereof. The fungus may be isolated from the fermented food or the environment, or may be cultured. The cells may be dead cells or live cells. The cells may exist in a culture medium, buffer solution, or the like, or may be concentrated to remove the liquid, a lyophilized product thereof, or a frozen stock.
菌体培養物は、細菌の分泌物、代謝物等を含んでよい。菌体培養物には、細菌が産生するペプチド、タンパク質、糖、酵素、有機酸およびこれらを含む培地(液体培地および固形培地)が含まれ得る。菌体培養物は、細菌を培養した後の上清であってもよい。培養上清は、例えば細菌を培養した液体培地から遠心分離、ろ過操作等で細菌を除いて得ることができる。
The bacterial cell culture may contain bacterial secretions, metabolites, and the like. Cell cultures can contain peptides, proteins, sugars, enzymes, organic acids produced by bacteria, and media containing these (liquid media and solid media). The cell culture may be the supernatant after culturing bacteria. The culture supernatant can be obtained, for example, by removing bacteria from a liquid medium in which bacteria have been cultured, by centrifugation, filtration, or the like.
NITE-BP-03198、NITE-BP-03199、NITE-BP-03200、NITE-BP-03201およびNITE-BP-03202は、乳酸菌の通常の培養方法に従って培養することができる。代表的な培養方法としては、MRS(de Man,Rogosa and Sharpe)液体培地またはMRS寒天培地を用いて温度30℃で培養する方法が挙げられる。
NITE-BP-03198, NITE-BP-03199, NITE-BP-03200, NITE-BP-03201 and NITE-BP-03202 can be cultured according to a normal culture method for lactic acid bacteria. A typical culture method includes a method of culturing at a temperature of 30° C. using MRS (de Mann, Rogosa and Sharpe) liquid medium or MRS agar medium.
菌体または菌体培養物の抽出物は、上記乳酸菌の菌体または菌体培養物が有する歯周病菌に対する抗菌活性を失わないように調製される。抽出物は、例えば細菌の菌体または菌体培養物を超音波破砕、ビーズ摩砕、凍結融解、化学的溶解等の処理をすることにより得ることができる。抽出物は、菌体または菌体培養物を塩析、限外ろ過、イオン交換クロマトグラフィーまたは有機溶媒を用いた液相抽出等を行って得てもよい。これらの処理は適宜組合わせて行なうことができる。抽出物は、細菌の菌体の断片、核酸、ペプチド、タンパク質、糖および酵素を含み得る。本明細書において、細菌の菌体もしくは菌体培養物またはこれらの抽出物を「菌体調製物」とも記す。
The bacterial cell or bacterial cell culture extract is prepared so as not to lose the antibacterial activity against periodontal disease bacteria possessed by the lactic acid bacteria cell or bacterial cell culture. Extracts can be obtained, for example, by subjecting bacterial cells or cell cultures to ultrasonic disruption, bead grinding, freeze-thawing, chemical lysis, or the like. The extract may be obtained by salting-out, ultrafiltration, ion-exchange chromatography, liquid-phase extraction using an organic solvent, or the like, on the cells or cell culture. These treatments can be performed in combination as appropriate. The extract may contain bacterial cell fragments, nucleic acids, peptides, proteins, sugars and enzymes. In the present specification, bacterial cells, bacterial cell cultures, or extracts thereof are also referred to as "microbial cell preparations."
口腔用組成物は、口腔から体内に摂取される経口組成物であってよい。口腔用組成物は、食品であってよく、ヒト以外の動物の食品または飼料であってよい。口腔用組成物は、口腔内で使用され、使用後は口腔内から排出される組成物であってもよい。口腔用組成物は、口腔外で使用される組成物であってもよい。口腔外で使用される組成物は、例えば、義歯洗浄剤であってもよい。口腔用組成物は、例えば口腔ケア用品であってよい。
The oral composition may be an oral composition that is taken into the body through the oral cavity. The oral composition may be a food product and may be a non-human animal food or feed. The oral composition may be a composition that is used in the oral cavity and is discharged from the oral cavity after use. The oral composition may be a composition for extra-oral use. The composition for extraoral use may be, for example, a denture cleanser. The oral composition can be, for example, an oral care product.
口腔用組成物は、好ましくは経口組成物は、本発明の効果を損なわない範囲で添加成分を配合することができる。経口摂取に適した添加成分としては、水等の溶媒、糖質、タンパク質、脂質、ビタミン類、ミネラル類、生体必須微量金属(硫酸マンガン、硫酸亜鉛、塩化マグネシウム、炭酸カリウム等)、香料、食品衛生上または薬学的に許容可能な担体、食品添加物等が挙げられる。添加成分は、1種または2種以上の組み合わせを適宜選択して、必要に応じて配合することができる。
The oral composition, preferably the oral composition, can contain additive components within a range that does not impair the effects of the present invention. Additives suitable for oral intake include solvents such as water, carbohydrates, proteins, lipids, vitamins, minerals, trace metals essential for living organisms (manganese sulfate, zinc sulfate, magnesium chloride, potassium carbonate, etc.), fragrances, and foods. sanitary or pharmaceutically acceptable carriers, food additives and the like. Additive components can be added as needed by appropriately selecting one or a combination of two or more.
糖質としては、糖類、加工澱粉(デキストリン、可溶性澱粉、ブリティッシュスターチ、酸化澱粉、澱粉エステル、澱粉エーテル等)、食物繊維等が挙げられる。
Carbohydrates include saccharides, processed starch (dextrin, soluble starch, British starch, oxidized starch, starch ester, starch ether, etc.), dietary fiber, and the like.
タンパク質としては、全脂粉乳、脱脂粉乳、部分脱脂粉乳、カゼイン、ホエイ粉、ホエイタンパク質、ホエイタンパク質濃縮物、ホエイタンパク質分離物、α-カゼイン、β-カゼイン、κ-カゼイン、β-ラクトグロブリン、α-ラクトアルブミン、ラクトフェリン、大豆タンパク質、鶏卵タンパク質、および肉タンパク質等の動植物性タンパク質、ならびにこれらの加水分解物、ならびに、バター、乳性ミネラル、クリーム、ホエイ、非タンパク態窒素、シアル酸、リン脂質、および乳糖等の各種乳由来成分等が挙げられる。
Proteins include whole milk powder, skimmed milk powder, partially skimmed milk powder, casein, whey powder, whey protein, whey protein concentrate, whey protein isolate, α-casein, β-casein, κ-casein, β-lactoglobulin, Animal and plant proteins such as α-lactalbumin, lactoferrin, soy protein, chicken egg protein, and meat protein, and their hydrolysates, as well as butter, milk minerals, cream, whey, non-protein nitrogen, sialic acid, and phosphorus Examples include lipids and various milk-derived components such as lactose.
脂質としては、ラード、魚油等、これらの分別油、これらの水素添加油、およびこれらのエステル交換油等の動物性油脂、ならびに、パーム油、サフラワー油、コーン油、ナタネ油、ヤシ油、これらの分別油、これらの水素添加油、およびこれらのエステル交換油等の植物性油脂等が挙げられる。
Lipids include animal oils such as lard, fish oil, fractionated oils thereof, hydrogenated oils thereof, transesterified oils thereof, palm oil, safflower oil, corn oil, rapeseed oil, coconut oil, Vegetable oils and fats such as these fractionated oils, these hydrogenated oils, and these interesterified oils are included.
ビタミン類としては、ビタミンA、カロチン類、ビタミンB群、ビタミンC、ビタミンD群、ビタミンE、ビタミンK群、ビタミンP、ビタミンQ、ナイアシン、ニコチン酸、パントテン酸、ビオチン、イノシトール、コリン、葉酸等が挙げられる。
Vitamins include vitamin A, carotene, vitamin B group, vitamin C, vitamin D group, vitamin E, vitamin K group, vitamin P, vitamin Q, niacin, nicotinic acid, pantothenic acid, biotin, inositol, choline, and folic acid. etc.
ミネラル類としては、カルシウム、カリウム、マグネシウム、ナトリウム、銅、鉄、マンガン、亜鉛、セレン等が挙げられる。
Minerals include calcium, potassium, magnesium, sodium, copper, iron, manganese, zinc, and selenium.
口腔用組成物(好ましくは経口組成物)は、溶液、懸濁液、乳濁液、粉末、ペースト、半固体成形物、固体成形物等、経口摂取可能な形態であればよい。食品(飲料を含む)としては、例えば、牛乳、植物性ミルク、乳飲料、清涼飲料、発酵乳、乳酸菌飲料、乳性飲料、調製粉乳、液体ミルク、流動食、病者用食品、冷凍食品、発酵食品、加工食品、菓子類、調味料その他の市販食品等が挙げられる。より具体的には、ヨーグルト、チーズ、アイスクリーム、氷菓、チョコレート、タブレット(錠菓)、グミ、キャンディー、ゼリー、ガム、パン、ビスケット、クラッカー、ピッツァクラスト等が挙げられる。口腔用組成物は、サプリメント、健康食品、機能性食品、特別用途食品、保健機能食品、特定保健用食品、栄養機能食品、機能性表示食品、医薬用部外品、化粧品等であってもよく、錠剤、カプセル剤、散剤、顆粒剤、ゼリー剤等であってもよい。
The oral composition (preferably oral composition) may be in an orally ingestible form such as solution, suspension, emulsion, powder, paste, semi-solid molding, or solid molding. Foods (including beverages) include, for example, milk, vegetable milk, milk beverages, soft drinks, fermented milk, lactic acid beverages, lactic beverages, infant formula, liquid milk, liquid diets, foods for the sick, frozen foods, Examples include fermented foods, processed foods, confectionery, seasonings and other commercially available foods. More specific examples include yoghurt, cheese, ice cream, ice cream, chocolate, tablets, gummies, candies, jellies, gums, breads, biscuits, crackers, pizza crusts, and the like. The oral composition may be supplements, health foods, functional foods, foods for special dietary uses, foods with health claims, foods for specified health uses, foods with nutrient function claims, foods with function claims, quasi-drugs, cosmetics, and the like. , tablets, capsules, powders, granules, jelly and the like.
口腔用組成物は、好ましくは口腔ケア用品は、本発明の効果を損なわない範囲で、添加成分を配合することができる。添加成分としては、例えばフッ素化合物、薬用成分、研磨剤、粘結剤、粘稠剤、界面活性剤、矯味剤、防腐剤、香料、着色剤、pH調整剤、溶剤、可溶化剤、基剤、洗浄剤、吸着剤等が挙げられる。添加成分は、組成物の剤形に応じて適宜選択し得る。添加成分は、1種または2種以上の組み合わせを適宜選択して、必要に応じて配合することができる。
The oral composition, preferably the oral care product, can contain additive components within a range that does not impair the effects of the present invention. Examples of additive components include fluorine compounds, medicinal ingredients, abrasives, binders, thickening agents, surfactants, corrigents, preservatives, fragrances, coloring agents, pH adjusters, solvents, solubilizers, and bases. , detergents, adsorbents, and the like. The additive component can be appropriately selected according to the dosage form of the composition. Additive components can be added as needed by appropriately selecting one or a combination of two or more.
フッ素化合物としては、フッ化ナトリウム、フッ化カリウム、フッ化アンモニウム、フッ化スズ、アミンフッ化物、モノフルオロリン酸ナトリウム、モノフルオロリン酸カリウム、フッ化ケイ素ナトリウム、フッ化ケイ素カルシウム等が挙げられ、好ましくはフッ化ナトリウムまたはモノフルオロリン酸ナトリウムである。フッ素化合物は、う蝕を抑制することができる。
Examples of fluorine compounds include sodium fluoride, potassium fluoride, ammonium fluoride, tin fluoride, amine fluoride, sodium monofluorophosphate, potassium monofluorophosphate, sodium silicon fluoride, and calcium silicon fluoride. Sodium fluoride or sodium monofluorophosphate is preferred. Fluorine compounds can inhibit caries.
フッ素化合物は、組成物中の濃度が例えばフッ素濃度として1001ppm~3000ppm、好ましくは1001ppm~2000ppm、より好ましくは1001ppm~1500ppmとなる量で使用される。
The fluorine compound is used in an amount such that the fluorine concentration in the composition is, for example, 1001 ppm to 3000 ppm, preferably 1001 ppm to 2000 ppm, more preferably 1001 ppm to 1500 ppm.
薬用成分としては、殺菌剤、抗炎症剤、血行促進剤、歯石沈着抑制剤、ステイン除去剤、知覚過敏抑制剤、ビタミン剤、生薬エキス、歯垢分解酵素等を、上記口腔用組成物に配合することができる。これらの薬効成分は、医薬品等に使用しうるものであれば特に限定されない。
As medicinal ingredients, bactericides, anti-inflammatory agents, blood circulation promoters, tartar deposition inhibitors, stain removers, hypersensitivity inhibitors, vitamins, crude drug extracts, plaque-degrading enzymes, etc. are added to the oral composition. can do. These medicinal ingredients are not particularly limited as long as they can be used for pharmaceuticals and the like.
殺菌剤としては、塩化セチルピリジニウム、塩化ベンザルコニウム、塩化ベンゼトニウム、塩酸クロルヘキシジン、およびグルコン酸クロルヘキシジン等のカチオン性殺菌剤;ドデシルジアミノエチルグリシン等の両性殺菌剤;トリクロサン、およびイソプロピルメチルフェノール等の非イオン性殺菌剤;ならびに、ヒノキチオール等が挙げられる。
Bactericides include cationic fungicides such as cetylpyridinium chloride, benzalkonium chloride, benzethonium chloride, chlorhexidine hydrochloride, and chlorhexidine gluconate; amphoteric fungicides such as dodecyldiaminoethylglycine; ionic fungicides; and hinokitiol and the like.
抗炎症剤としては、β-グリチルレチン酸、グリチルレチン酸、グリチルリチン酸、グリチルリチン酸二アンモニウム、グリチルリチン酸二ナトリウム、グリチルリチン酸三ナトリウム、グリチルリチン酸二カリウム、グリチルリチン酸モノアンモニウム、ε-アミノカプロン酸、アズレンスルホン酸ナトリウム水和物、アラントイン、アラントインクロルヒドトキシアルミニウム、アルクロキサ、アラントインジヒドロキシアルミニウム、アルジオキサ、エピジヒドロコレステリン、ジヒドロコレステロール、リゾチーム塩酸塩等が挙げられる。
Anti-inflammatory agents include β-glycyrrhetinic acid, glycyrrhetinic acid, glycyrrhizic acid, diammonium glycyrrhizinate, disodium glycyrrhizinate, trisodium glycyrrhizinate, dipotassium glycyrrhizinate, monoammonium glycyrrhizinate, ε-aminocaproic acid, azulene sulfonic acid. Sodium hydrate, allantoin, allantoin chlorohydroxyaluminum, alcloxa, allantoin dihydroxyaluminum, aldioxa, epidihydrocholesterin, dihydrocholesterol, lysozyme hydrochloride and the like.
血行促進剤としては、塩化ナトリウム等が挙げられる。
Examples of blood circulation promoting agents include sodium chloride.
歯石沈着抑制剤としては、ゼオライト、リン酸水素二ナトリウム、ピロリン酸二水素二ナトリウム、ピロリン酸ナトリウム、無水ピロリン酸ナトリウム、ピロリン酸四ナトリウム(無水)、リン酸一水素二ナトリウム、リン酸水素ナトリウム水和物、リン酸水素二ナトリウム(結晶)、リン酸三ナトリウム、ポリリン酸ナトリウム等が挙げられる。
As a tartar deposition inhibitor, zeolite, disodium hydrogen phosphate, disodium dihydrogen pyrophosphate, sodium pyrophosphate, anhydrous sodium pyrophosphate, tetrasodium pyrophosphate (anhydrous), disodium monohydrogen phosphate, sodium hydrogen phosphate hydrate, disodium hydrogen phosphate (crystal), trisodium phosphate, sodium polyphosphate and the like.
ステイン除去剤としては、マクロゴール(マクロゴール200、マクロゴール300、マクロゴール400、マクロゴール600、マクロゴール1000、マクロゴール1500、マクロゴール1540、マクロゴール4000、マクロゴール6000、マクロゴール20000など)、ポリリン酸ナトリウム、ポリビニルピロリドン等が挙げられる。
As a stain remover, macrogol (Macrogol 200, Macrogol 300, Macrogol 400, Macrogol 600, Macrogol 1000, Macrogol 1500, Macrogol 1540, Macrogol 4000, Macrogol 6000, Macrogol 20000, etc.) , sodium polyphosphate, polyvinylpyrrolidone, and the like.
知覚過敏抑制剤としては、硝酸カリウム、乳酸アルミニウム等が挙げられる。
Examples of antihypersensitivity agents include potassium nitrate and aluminum lactate.
ビタミン剤としては、アスコルビン酸、L-アスコルビン酸、アスコルビン酸ナトリウム、L-アスコルビン酸ナトリウム、ピリドキシン塩酸塩、酢酸DL-α-トコフェロール、トコフェロール酢酸エステル、ニコチン酸dl-α-トコフェロール、トコフェロールニコチン酸エステル等が挙げられる。
Vitamin preparations include ascorbic acid, L-ascorbic acid, sodium ascorbate, sodium L-ascorbate, pyridoxine hydrochloride, DL-α-tocopherol acetate, tocopherol acetate, dl-α-tocopherol nicotinate, tocopherol nicotinate etc.
研磨剤としては、無水ケイ酸、シリカ(結晶性シリカ又は非晶性シリカ)、シリカゲル、およびアルミノシリケート等のシリカ系研磨剤、ゼオライト、リン酸水素カルシウム無水和物、リン酸水素カルシウム2水和物、ピロリン酸カルシウム、炭酸カルシウム、水酸化アルミニウム、アルミナ、炭酸マグネシウム、第3リン酸マグネシウム、ケイ酸ジルコニウム、第3リン酸カルシウム、ハイドロキシアパタイト、第4リン酸カルシウム、ならびに、合成樹脂系研磨剤等が挙げられる。
Examples of abrasives include silicic anhydride, silica (crystalline silica or amorphous silica), silica gel, silica-based abrasives such as aluminosilicate, zeolite, calcium hydrogen phosphate anhydrate, and calcium hydrogen phosphate dihydrate. substances, calcium pyrophosphate, calcium carbonate, aluminum hydroxide, alumina, magnesium carbonate, magnesium phosphate tertiary, zirconium silicate, calcium phosphate tertiary, hydroxyapatite, calcium tetraphosphate, and synthetic resin abrasives.
粘結剤としては、プルラン、ゼラチン、メチルセルロース、ヒドロキシエチルセルロース、ヒドロキシプロピルセルロース、カルボキシメチルセルロースナトリウム、カラギーナン、アルギン酸ナトリウム、キサンタンガム、ポリアクリル酸ナトリウム、アラビアガム、グアーガム、ローカストビーンガム、ポリビニルアルコール、ポリビニルピロリドン、およびカルボキシビニルポリマー等の有機系粘結剤、ならびに、増粘性無水ケイ酸、およびベントナイト等の無機系粘結剤等が挙げられる。
Binders include pullulan, gelatin, methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, sodium carboxymethylcellulose, carrageenan, sodium alginate, xanthan gum, sodium polyacrylate, gum arabic, guar gum, locust bean gum, polyvinyl alcohol, polyvinylpyrrolidone, and organic binders such as carboxyvinyl polymer, and inorganic binders such as thickening silicic anhydride and bentonite.
粘稠剤としては、多価アルコール(さらに具体的には、ソルビット、グリセリン、濃グリセリン、エチレングリコール、プロピレングリコール、1,3-ブチレングリコール、プロパンジオール(1,3-プロパンジオール)、ポリエチレングリコール、ポリプロピレングリコール、キシリトール、マルチトール、ラクチトール等)、トレハロース、ヒアルロン酸ナトリウム、加水分解コラーゲン等が挙げられる。
Examples of thickening agents include polyhydric alcohols (more specifically, sorbitol, glycerin, concentrated glycerin, ethylene glycol, propylene glycol, 1,3-butylene glycol, propanediol (1,3-propanediol), polyethylene glycol, polypropylene glycol, xylitol, maltitol, lactitol, etc.), trehalose, sodium hyaluronate, hydrolyzed collagen, and the like.
界面活性剤としては、アニオン界面活性剤では、N-アシルアミノ酸塩、α-オレフィンスルホン酸塩、N-アシルスルホン酸塩、アルキル硫酸塩(例えば、ラウリル硫酸ナトリウムなど)、グリセリン脂肪酸エステルの硫酸塩等が挙げられる。
ノニオン界面活性剤としては、ポリオキシエチレンアルキルエーテル、ポリオキシエチレン-ポリオキシプロピレンブロック共重合体、ポリオキシエチレン硬化ヒマシ油、グリセリンエステルのポリオキシエチレンエーテル、ショ糖脂肪酸エステル、アルキロールアミド、グリセリン脂肪酸エステル、アルキルグリコシド等が挙げられる。
両性界面活性剤としては、アルキルベタイン系界面活性剤、アミンオキサイド系界面活性剤、イミダゾリニウムベタイン系界面活性剤が挙げられる。これらの具体例としては、2-アルキル-N-カルボキシメチル-N-ヒドロキシエチルイミダゾリニウムベタイン、ラウリルジメチルアミノ酢酸ベタイン、ヤシ油アルキルベタイン(ヤシ油アルキルジメチルアミノ酢酸ベタイン)、ステアリルジメチルアミノ酢酸ベタイン、ステアリルジメチルベタインナトリウム、ヤシ油脂肪酸アミドアルキルベタイン、パーム油脂肪酸アミドプロピルベタイン、ラウリン酸アミドプロピルベタイン、リシノレイン酸アミドプロピルベタイン、ステアリルジヒドロキシエチルベタイン等が挙げられる。 Surfactants include anionic surfactants such as N-acyl amino acid salts, α-olefin sulfonates, N-acyl sulfonates, alkyl sulfates (eg, sodium lauryl sulfate, etc.), sulfates of glycerin fatty acid esters. etc.
Nonionic surfactants include polyoxyethylene alkyl ether, polyoxyethylene-polyoxypropylene block copolymer, polyoxyethylene hydrogenated castor oil, polyoxyethylene ether of glycerin ester, sucrose fatty acid ester, alkylolamide, glycerin. fatty acid esters, alkyl glycosides, and the like;
Amphoteric surfactants include alkyl betaine surfactants, amine oxide surfactants, and imidazolinium betaine surfactants. Specific examples of these include 2-alkyl-N-carboxymethyl-N-hydroxyethylimidazolinium betaine, lauryldimethylaminoacetic acid betaine, coconut oil alkylbetaine (coconut alkyldimethylaminoacetic acid betaine), stearyldimethylaminoacetic acid betaine. .
ノニオン界面活性剤としては、ポリオキシエチレンアルキルエーテル、ポリオキシエチレン-ポリオキシプロピレンブロック共重合体、ポリオキシエチレン硬化ヒマシ油、グリセリンエステルのポリオキシエチレンエーテル、ショ糖脂肪酸エステル、アルキロールアミド、グリセリン脂肪酸エステル、アルキルグリコシド等が挙げられる。
両性界面活性剤としては、アルキルベタイン系界面活性剤、アミンオキサイド系界面活性剤、イミダゾリニウムベタイン系界面活性剤が挙げられる。これらの具体例としては、2-アルキル-N-カルボキシメチル-N-ヒドロキシエチルイミダゾリニウムベタイン、ラウリルジメチルアミノ酢酸ベタイン、ヤシ油アルキルベタイン(ヤシ油アルキルジメチルアミノ酢酸ベタイン)、ステアリルジメチルアミノ酢酸ベタイン、ステアリルジメチルベタインナトリウム、ヤシ油脂肪酸アミドアルキルベタイン、パーム油脂肪酸アミドプロピルベタイン、ラウリン酸アミドプロピルベタイン、リシノレイン酸アミドプロピルベタイン、ステアリルジヒドロキシエチルベタイン等が挙げられる。 Surfactants include anionic surfactants such as N-acyl amino acid salts, α-olefin sulfonates, N-acyl sulfonates, alkyl sulfates (eg, sodium lauryl sulfate, etc.), sulfates of glycerin fatty acid esters. etc.
Nonionic surfactants include polyoxyethylene alkyl ether, polyoxyethylene-polyoxypropylene block copolymer, polyoxyethylene hydrogenated castor oil, polyoxyethylene ether of glycerin ester, sucrose fatty acid ester, alkylolamide, glycerin. fatty acid esters, alkyl glycosides, and the like;
Amphoteric surfactants include alkyl betaine surfactants, amine oxide surfactants, and imidazolinium betaine surfactants. Specific examples of these include 2-alkyl-N-carboxymethyl-N-hydroxyethylimidazolinium betaine, lauryldimethylaminoacetic acid betaine, coconut oil alkylbetaine (coconut alkyldimethylaminoacetic acid betaine), stearyldimethylaminoacetic acid betaine. .
矯味剤としては、例えば、L-グルタミン酸ナトリウム、サッカリン、サッカリンナトリウム、グリチルリチン酸二ナトリウム、グリチルリチン酸三ナトリウム、ショ糖、ブドウ糖、果糖、乳糖、ハチミツ、アスパルテーム、ステビア、スクラロース、キシリトール、イノシトール、D-ソルビトール、D-マンニトール、アラビトール、ラフィノース、ラクチュロース、ラクチトール、エリスリトール、還元パラチノース、パラチノース、パラチニット、アセスルファムK、マルトース、マルトシルトレハロース、マルチトール、ネオヘスペリジンジヒドロカルコン、ペリラルチン、p-メトキシシンナミックアルデヒド、ソーマチン等が挙げられる。
Examples of flavoring agents include sodium L-glutamate, saccharin, sodium saccharin, disodium glycyrrhizinate, trisodium glycyrrhizinate, sucrose, glucose, fructose, lactose, honey, aspartame, stevia, sucralose, xylitol, inositol, and D-sorbitol. , D-mannitol, arabitol, raffinose, lactulose, lactitol, erythritol, reduced palatinose, palatinose, palatinit, acesulfame K, maltose, maltosyltrehalose, maltitol, neohesperidin dihydrochalcone, perillartine, p-methoxycinnamic aldehyde, thaumatin, etc. is mentioned.
防腐剤としては、例えば、グリシン、安息香酸ナトリウム、メチルパラベン、エチルパラベン、ブチルパラベン、イソプロピルパラベン、プロピルパラベン、イソブチルパラベン、およびベンジルパラベン等のパラオキシ安息香酸エステル、フェノキシエタノール、およびエタノール等のアルコール類、ソルビン酸、安息香酸、デヒドロ酢酸、プロピオン酸およびこれらの塩、エチレンジアミン四酢酸塩、塩化ベンザルコニウム、塩化ベンゼトニウム、塩化セチルピリジニウム、ならびに、塩酸アルキルジアミノエチルグリシン等が挙げられる。
Examples of antiseptics include glycine, sodium benzoate, paraoxybenzoic acid esters such as methylparaben, ethylparaben, butylparaben, isopropylparaben, propylparaben, isobutylparaben, and benzylparaben; alcohols such as phenoxyethanol and ethanol; acid, benzoic acid, dehydroacetic acid, propionic acid and salts thereof, ethylenediaminetetraacetate, benzalkonium chloride, benzethonium chloride, cetylpyridinium chloride, and alkyldiaminoethylglycine hydrochloride.
香料としては、例えば、L-メントール、ペパーミント、スペアミント、フルーツ香料、ハッカ油等が挙げられる。香料は、唾液分泌を刺激するという利点も有する。
Flavors include, for example, L-menthol, peppermint, spearmint, fruit flavors, and peppermint oil. Perfumes also have the advantage of stimulating salivation.
着色剤としては、ベニバナ赤色素、クチナシ黄色素、クチナシ青色素、シソ色素、紅麹色素、赤キャベツ色素、ニンジン色素、ハイビスカス色素、カカオ色素、スピルリナ青色素、およびクマリンド色素等の天然色素、赤色3号、赤色104号、赤色105号、赤色106号、黄色4号、黄色5号、緑色3号、および青色1号等の法定色素、リボフラビン、銅クロロフィリンナトリウム、ならびに、二酸化チタン等が挙げられる。
Coloring agents include safflower red pigment, gardenia yellow pigment, gardenia blue pigment, perilla pigment, monascus pigment, red cabbage pigment, carrot pigment, hibiscus pigment, cacao pigment, spirulina blue pigment, and natural pigment such as coumarind pigment, red Legal pigments such as No. 3, Red No. 104, Red No. 105, Red No. 106, Yellow No. 4, Yellow No. 5, Green No. 3, and Blue No. 1, riboflavin, sodium copper chlorophyllin, and titanium dioxide. .
pH調整剤としては、ギ酸、乳酸、酢酸、塩酸、硫酸、硝酸、クエン酸、リン酸、リンゴ酸、グルコン酸、マレイン酸、コハク酸、グルタミン酸、ピロリン酸、酒石酸、酢酸水酸化ナトリウム、水酸化カリウム、酢酸ナトリウム、炭酸ナトリウム、クエン酸ナトリウム、クエン酸水素ナトリウム、リン酸、リン酸ナトリウム、リン酸一水素ナトリウム、およびリン酸二水素ナトリウムリン酸二水素カリウム等の酸、アルカリ、および緩衝剤等が挙げられる。
pH adjusters include formic acid, lactic acid, acetic acid, hydrochloric acid, sulfuric acid, nitric acid, citric acid, phosphoric acid, malic acid, gluconic acid, maleic acid, succinic acid, glutamic acid, pyrophosphoric acid, tartaric acid, sodium acetate hydroxide, hydroxide Acids, alkalis, and buffers such as potassium, sodium acetate, sodium carbonate, sodium citrate, sodium hydrogen citrate, phosphoric acid, sodium phosphate, sodium monohydrogen phosphate, and sodium dihydrogen phosphate potassium dihydrogen phosphate etc.
溶剤としては、水、ならびに、エタノール、およびプロパノールなどの低級アルコール等が挙げられる。
Examples of solvents include water and lower alcohols such as ethanol and propanol.
可溶化剤は、水への上記添加剤または薬効成分の溶解を促進させるために添加してもよい。そのような可溶化剤の例として、プロピレングリコール、ジプロピレングリコール、ブチレングリコール、およびポリエチレングリコール等の多価アルコール類等を挙げることができる。
A solubilizer may be added to promote the dissolution of the above additives or medicinal ingredients in water. Examples of such solubilizers include polyhydric alcohols such as propylene glycol, dipropylene glycol, butylene glycol, and polyethylene glycol.
基剤としては、炭酸水素ナトリウム等が挙げられる。
Examples of bases include sodium hydrogen carbonate.
洗浄剤としては、ポリリン酸ナトリウムなどを挙げることができる。
Examples of cleaning agents include sodium polyphosphate.
吸着剤としては、β-シクロデキストリンなどを挙げることができる。
Examples of adsorbents include β-cyclodextrin.
口腔用組成物は、例えば洗口剤(マウスウォッシュ)、歯磨剤(練歯磨、液体歯磨、歯磨粉等)、口中清涼剤、ガム剤、トローチ剤、バッカル錠、歯肉付着性テープ製剤、口腔内用ゲル製剤、口腔内用軟膏、口腔内用スプレー剤、口腔内用パスタ剤、口腔内用ペースト剤、口腔用丸剤、口腔内用錠剤、口腔用散剤、口腔内用粉剤、口腔内用液剤、口腔内用懸濁剤、口腔内用乳剤、口腔内用顆粒剤、口腔内用カプセル剤、義歯洗浄剤が挙げられる。口腔用組成物は、好ましくは洗口剤または歯磨剤である。口腔用組成物は、医薬部外品、衛生用品または化粧品であってもよい。
Oral compositions include, for example, mouthwashes, dentifrices (toothpaste, liquid toothpaste, toothpaste, etc.), mouth fresheners, gums, lozenges, buccal tablets, gingival adhesive tape preparations, intraoral oral gel, oral ointment, oral spray, oral paste, oral paste, oral pill, oral tablet, oral powder, oral powder, oral liquid , intraoral suspensions, intraoral emulsions, intraoral granules, intraoral capsules, and denture cleaners. The oral composition is preferably a mouthwash or dentifrice. Oral compositions may be quasi-drugs, hygiene products or cosmetics.
口腔用組成物の製造方法は特に限定されない。口腔用組成物は、一般的な経口組成物および口腔ケア用品等が製造される任意の製造方法によって製造されてよい。口腔用組成物の製造方法は、例えば一般的な経口組成物および口腔ケア用等の製造方法のいずれかの工程において、上記乳酸菌の菌体調製物を添加する工程を含んでよい。また、口腔用組成物の製造方法は、例えば、製造された経口組成物および口腔ケア用品等に、上記乳酸菌の菌体調製物を添加する工程を含んでよい。口腔用組成物は、上記乳酸菌の菌体調製物そのものであってもよい。口腔用組成物は、上記乳酸菌の菌体調製物を経口組成物および口腔ケア用品等に付着、吸収または混合させやすくするための液体、展着剤等を含んでよい。
The manufacturing method of the oral composition is not particularly limited. The oral composition may be manufactured by any manufacturing method by which common oral compositions, oral care products, and the like are manufactured. A method for producing an oral composition may include a step of adding the cell preparation of the lactic acid bacterium to any step of a general oral composition, an oral care composition, or the like. In addition, the method for producing an oral composition may include, for example, a step of adding the cell preparation of lactic acid bacteria to the oral composition, oral care product and the like produced. The composition for oral cavity may be the bacterial cell preparation itself of the above-mentioned lactic acid bacteria. The oral composition may contain liquids, spreading agents, and the like to facilitate the attachment, absorption, or mixing of the lactic acid bacteria cell preparation with the oral composition, oral care products, and the like.
口腔用組成物に含まれる上記乳酸菌の菌体調製物の量は、歯周病菌に対する抗菌活性を示す程度であれば特に限定されない。口腔用組成物中の上記乳酸菌の菌体調製物の合計量は、例えば1×103~1×1012cfu(コロニー形成単位)/gであってもよく、1×104~1×1012cfu/gであってもよく、1×105~1×1012cfu/gであってもよい。上記コロニー形成単位は、寒天平板培養法によって求めることができる。口腔用組成物中の上記乳酸菌の菌体調製物の合計量(含有割合)は、口腔用組成物重量に対して0.0001質量%~30質量%、好ましくは0.001質量%~10質量%であってよい。口腔用組成物中の上記乳酸菌の菌体調製物の合計の濃度は、0.1~100,000ppmであってもよく、1~100,000ppmであってもよく、10~100,000ppmであってもよい。当該合計量は、天秤等で秤量可能である。
The amount of the lactic acid bacteria cell preparation contained in the oral cavity composition is not particularly limited as long as it exhibits an antibacterial activity against periodontal disease bacteria. The total amount of the cell preparation of lactic acid bacteria in the oral composition may be, for example, 1× 10 3 to 1×10 12 cfu (colony forming units)/g. 12 cfu/g, or 1×10 5 to 1×10 12 cfu/g. The colony-forming unit can be determined by an agar plate culture method. The total amount (content ratio) of the bacterial cell preparation of lactic acid bacteria in the oral composition is 0.0001% by mass to 30% by mass, preferably 0.001% by mass to 10% by mass relative to the weight of the oral composition. %. The total concentration of the lactic acid bacteria cell preparation in the oral composition may be 0.1 to 100,000 ppm, may be 1 to 100,000 ppm, or may be 10 to 100,000 ppm. may The total amount can be weighed with a balance or the like.
口腔用組成物は、動物へ適用し得る。動物は、ヒトまたはヒト以外の動物であってよい。動物は、哺乳類を含む。哺乳類は、齧歯目、ウサギ目、食肉目、鯨偶蹄目、奇蹄目、霊長目を含んでよい。より具体的には上記哺乳類は、マウス、ラット、ハムスター、モルモット、ハリネズミ、フェレット、ウサギ、イヌ、ネコ、ウシ、ブタ、ヤギ、ウマ、ヒツジ、サル、オランウータン、チンパンジー等が挙げられる。動物は、ペット、家畜または実験動物であってもよい。
The oral composition can be applied to animals. The animal may be a human or non-human animal. Animals include mammals. Mammals may include Rodentia, Lagomorpha, Carnivora, Cetatodactyla, Perissodactyla, Primate. More specifically, the above mammals include mice, rats, hamsters, guinea pigs, hedgehogs, ferrets, rabbits, dogs, cats, cows, pigs, goats, horses, sheep, monkeys, orangutans, chimpanzees and the like. Animals may be pets, farm animals or laboratory animals.
本発明の一実施形態は、口腔用組成物の製造におけるラクトバチルス・プランタラムの菌体もしくは菌体培養物またはこれらの抽出物の使用である。
One embodiment of the present invention is the use of Lactobacillus plantarum cells or cell cultures or extracts thereof in the production of oral compositions.
本発明に係る口腔用組成物は、口腔内疾患の予防または治療用組成物であってもよい。本明細書において、治療には、症状の緩和、症状の好転および完治を含む。予防または治療用組成物は、医薬品または動物用医薬品、医薬部外品、化粧品等であってよい。
The oral composition according to the present invention may be a preventive or therapeutic composition for oral diseases. As used herein, treatment includes alleviation of symptoms, amelioration of symptoms, and complete cure. The prophylactic or therapeutic composition may be pharmaceuticals or veterinary drugs, quasi-drugs, cosmetics, and the like.
ラクトバチルス・プランタラムは、口腔内疾患の原因菌に対して抗菌活性を示すため、ラクトバチルス・プランタラムを用いて口腔内疾患を予防または治療することができる。口腔内疾患としては、歯肉炎、および歯周炎等の歯周病;う蝕;口腔カンジダ症;粘膜炎;舌炎;口唇炎;ならびに、口角炎等が挙げられる。歯周病の原因菌としては、ポルフィロモナス・ジンジバリス(Porphyromonas gingivalis;以下、「P.g.菌」ともいう。)、タンネレラ・フォーサイシア(Tannerella forsythia;以下、T.f.菌」ともいう。)、トレポネーマ・デンティコーラ(Treponema denticola;以下、「T.d.菌」ともいう。)、プレボテラ・インターメディア(Prevotella intermedia)、アクチノバチルス・アクチノミセテムコミタンス(Actinobacillus actinomycetemcomitans)、フソバクテリウム・ヌクレアタム(Fusobacterium nucleatum)等が挙げられる。う蝕の原因菌としては、ストレプトコッカス・ミュータンス(Streptococcus mutans)、ストレプトコッカス・ソブリナス(Streptococcus sobrinus)等が挙げられる。カンジダ菌としては、カンジダ・アルビカンス(Candida albicans)、カンジダ・グラブラータ(Candida glabrata)、カンジダ・トロピカリス(Candida tropicalis)等が挙げられる。
Because Lactobacillus plantarum exhibits antimicrobial activity against causative bacteria of oral diseases, Lactobacillus plantarum can be used to prevent or treat oral diseases. Oral diseases include periodontal diseases such as gingivitis and periodontitis; dental caries; oral candidiasis; mucositis; glossitis; Bacteria that cause periodontal disease include Porphyromonas gingivalis (hereinafter also referred to as "Pg bacteria") and Tannerella forsythia (hereinafter also referred to as Tf bacteria). ), Treponema denticola (hereinafter also referred to as "T.d. bacteria"), Prevotella intermedia, Actinobacillus actinomycetemcomitans, Fusobacterium nucleatum nucleatum) and the like. Caries-causing bacteria include Streptococcus mutans, Streptococcus sobrinus, and the like. Candida fungi include Candida albicans, Candida glabrata, Candida tropicalis, and the like.
歯周病の原因菌のうち、P.g.菌、T.f.菌およびT.d.菌は、歯周病を重症化させる菌として知られている。ラクトバチルス・プランタラムの菌体もしくは菌体培養物またはこれらの抽出物は、悪性度が高い上記3つの歯周病菌の全てに対して抗菌活性を有する。従って、ラクトバチルス・プランタラムの菌体調製物を含む組成物は、口腔内疾患の予防または治療に効果的である。ラクトバチルス・プランタラムの菌体調製物を含む組成物は、抗生物質(ミノサイクリン等)および化学殺菌剤(塩化セチルピリジニウム(CPC)、イソプロピルメチルフェノール(IPMP)等)より口腔常在菌への影響が少ない。このため、ラクトバチルス・プランタラムの菌体調製物を含む組成物は、口腔微生物叢のバランスを崩しにくい。ラクトバチルス・プランタラムの菌体調製物は、歯垢形成を促進する細菌の増殖も抑制することができる。歯垢形成を促進する細菌としては、例えば、ストレプトコッカス・ゴルドニ(Streptococcus gordonii;以下、「ゴルドニ菌」ともいう。)が挙げられる。
Among the causative bacteria of periodontal disease, P. g. fungus, T. f. fungi and T. d. Bacteria are known to aggravate periodontal disease. Cells or cell cultures of Lactobacillus plantarum, or extracts thereof, have antibacterial activity against all of the above three highly malignant periodontal bacteria. Therefore, compositions containing a bacterial cell preparation of Lactobacillus plantarum are effective in preventing or treating oral diseases. Compositions containing bacterial cell preparations of Lactobacillus plantarum are more effective than antibiotics (minocycline, etc.) and chemical fungicides (cetylpyridinium chloride (CPC), isopropylmethylphenol (IPMP), etc.) on oral flora. Less is. For this reason, compositions containing a cell preparation of Lactobacillus plantarum are less likely to unbalance the oral microflora. Cell preparations of Lactobacillus plantarum can also inhibit the growth of bacteria that promote plaque formation. Bacteria that promote plaque formation include, for example, Streptococcus gordonii (hereinafter also referred to as “Gordonii”).
予防または治療用組成物は、口腔内疾患の原因菌に対する他の抗菌薬および抗生物質を含んでもよく、含まなくてもよい。予防または治療用組成物の剤型および製造方法は、上記組成物の剤型および製造方法と同じであってよい。予防または治療用組成物におけるラクトバチルス・プランタラムの菌体調製物の含有量は、歯周病菌に対する抗菌活性を示す程度であれば特に限定されず、上記口腔用組成物における含有量と同じ範囲であってよい。
The preventive or therapeutic composition may or may not contain other antibacterial agents and antibiotics against causative bacteria of oral diseases. The dosage form and manufacturing method of the preventive or therapeutic composition may be the same as the dosage form and manufacturing method of the composition described above. The content of the bacterial cell preparation of Lactobacillus plantarum in the preventive or therapeutic composition is not particularly limited as long as it exhibits antibacterial activity against periodontal disease bacteria, and is the same range as the content in the oral composition. can be
本発明の一実施形態は、口腔内疾患の予防または治療用組成物の製造におけるラクトバチルス・プランタラムの菌体もしくは菌体培養物またはこれらの抽出物の使用である。
One embodiment of the present invention is the use of Lactobacillus plantarum cells or cell cultures or extracts thereof in the manufacture of compositions for the prevention or treatment of oral diseases.
[口腔内疾患の予防または治療方法]
本発明の一実施形態に係る口腔内疾患の予防または治療方法は、ラクトバチルス・プランタラムの菌体もしくは菌体培養物またはこれらの抽出物を動物の口腔に適用することを含む。動物は、ヒトまたはヒト以外の動物であってよい。口腔内疾患としては、歯肉炎、および歯周炎等の歯周病;う蝕;口腔カンジダ症;粘膜炎;舌炎;口唇炎;ならびに、口角炎等が挙げられる。ラクトバチルス・プランタラムの菌体調製物は、経口摂取されてもよく、口腔内で使用後、口腔外に排出されてもよい。ラクトバチルス・プランタラムの菌体もしくは菌体培養物またはこれらの抽出物は、上記口腔内組成物として供給されてもよい。 [Method for preventing or treating oral diseases]
A method for preventing or treating oral diseases according to one embodiment of the present invention includes applying Lactobacillus plantarum cells or cell cultures or extracts thereof to the oral cavity of an animal. The animal may be a human or non-human animal. Oral diseases include periodontal diseases such as gingivitis and periodontitis; dental caries; oral candidiasis; mucositis; glossitis; The bacterial cell preparation of Lactobacillus plantarum may be orally ingested, or may be excreted out of the oral cavity after being used in the oral cavity. Cells or cell cultures of Lactobacillus plantarum or extracts thereof may be supplied as the intraoral composition.
本発明の一実施形態に係る口腔内疾患の予防または治療方法は、ラクトバチルス・プランタラムの菌体もしくは菌体培養物またはこれらの抽出物を動物の口腔に適用することを含む。動物は、ヒトまたはヒト以外の動物であってよい。口腔内疾患としては、歯肉炎、および歯周炎等の歯周病;う蝕;口腔カンジダ症;粘膜炎;舌炎;口唇炎;ならびに、口角炎等が挙げられる。ラクトバチルス・プランタラムの菌体調製物は、経口摂取されてもよく、口腔内で使用後、口腔外に排出されてもよい。ラクトバチルス・プランタラムの菌体もしくは菌体培養物またはこれらの抽出物は、上記口腔内組成物として供給されてもよい。 [Method for preventing or treating oral diseases]
A method for preventing or treating oral diseases according to one embodiment of the present invention includes applying Lactobacillus plantarum cells or cell cultures or extracts thereof to the oral cavity of an animal. The animal may be a human or non-human animal. Oral diseases include periodontal diseases such as gingivitis and periodontitis; dental caries; oral candidiasis; mucositis; glossitis; The bacterial cell preparation of Lactobacillus plantarum may be orally ingested, or may be excreted out of the oral cavity after being used in the oral cavity. Cells or cell cultures of Lactobacillus plantarum or extracts thereof may be supplied as the intraoral composition.
本発明の一実施形態は、口腔内疾患の予防または治療のためのラクトバチルス・プランタラムの菌体もしくは菌体培養物またはこれらの抽出物の使用である。
One embodiment of the present invention is the use of Lactobacillus plantarum cells or cell cultures or extracts thereof for the prevention or treatment of oral diseases.
[歯周病の原因菌に対する増殖抑制剤または殺菌剤、および歯周病の原因菌の増殖抑制方法または殺菌方法]
本発明の一実施形態に係る歯周病の原因菌に対する増殖抑制剤または殺菌剤は、ラクトバチルス・プランタラムの菌体もしくは菌体培養物またはこれらの抽出物を含む。歯周病の原因菌は、例えばポルフィロモナス・ジンジバリス、タンネレラ・フォーサイシアおよびトレポネーマ・デンティコーラから選択される少なくとも1つを含む。ラクトバチルス・プランタラムの菌体もしくは菌体培養物またはこれらの抽出物は、歯周病の原因菌を増殖抑制または殺菌することができ、特に上記3つの原因菌の全てに対する抗菌活性を有する。増殖抑制剤または殺菌剤は、上記口腔用組成物と同じ形態であってよい。増殖抑制剤または殺菌剤は、口腔内疾患の原因菌に対する他の抗菌薬および抗生物質を含んでもよく、含まなくてもよい。 [Growth inhibitor or bactericidal agent for periodontal disease-causing bacteria, and growth inhibitory method or sterilization method for periodontal disease-causing bacteria]
A growth inhibitor or fungicide for periodontal disease-causing bacteria according to one embodiment of the present invention contains Lactobacillus plantarum cells, cell cultures, or extracts thereof. Periodontal disease-causing bacteria include, for example, at least one selected from Porphyromonas gingivalis, Tannerella forsythia, and Treponema denticola. Lactobacillus plantarum cells, cell cultures, or extracts thereof can inhibit the growth of or kill periodontal disease-causing bacteria, and particularly have antibacterial activity against all of the above three causative bacteria. The antiproliferative agent or bactericidal agent may be in the same form as the oral composition. Antiproliferative agents or antiseptics may or may not include other antibacterial agents and antibiotics against causative agents of oral disease.
本発明の一実施形態に係る歯周病の原因菌に対する増殖抑制剤または殺菌剤は、ラクトバチルス・プランタラムの菌体もしくは菌体培養物またはこれらの抽出物を含む。歯周病の原因菌は、例えばポルフィロモナス・ジンジバリス、タンネレラ・フォーサイシアおよびトレポネーマ・デンティコーラから選択される少なくとも1つを含む。ラクトバチルス・プランタラムの菌体もしくは菌体培養物またはこれらの抽出物は、歯周病の原因菌を増殖抑制または殺菌することができ、特に上記3つの原因菌の全てに対する抗菌活性を有する。増殖抑制剤または殺菌剤は、上記口腔用組成物と同じ形態であってよい。増殖抑制剤または殺菌剤は、口腔内疾患の原因菌に対する他の抗菌薬および抗生物質を含んでもよく、含まなくてもよい。 [Growth inhibitor or bactericidal agent for periodontal disease-causing bacteria, and growth inhibitory method or sterilization method for periodontal disease-causing bacteria]
A growth inhibitor or fungicide for periodontal disease-causing bacteria according to one embodiment of the present invention contains Lactobacillus plantarum cells, cell cultures, or extracts thereof. Periodontal disease-causing bacteria include, for example, at least one selected from Porphyromonas gingivalis, Tannerella forsythia, and Treponema denticola. Lactobacillus plantarum cells, cell cultures, or extracts thereof can inhibit the growth of or kill periodontal disease-causing bacteria, and particularly have antibacterial activity against all of the above three causative bacteria. The antiproliferative agent or bactericidal agent may be in the same form as the oral composition. Antiproliferative agents or antiseptics may or may not include other antibacterial agents and antibiotics against causative agents of oral disease.
増殖抑制剤または殺菌剤に含まれる上記乳酸菌の菌体調製物の含有量は特に限定されないが、例えば1×103~1×1012cfu/mLであってもよく、1×105~1×1012cfu/mLであってもよく、1×107~1×1012cfu/mLであってもよい。上記コロニー形成単位は、寒天平板培養法によって求めることができる。増殖抑制剤または殺菌剤に含まれる上記乳酸菌の菌体調製物の合計の濃度は、特に限定されず、0.1~100,000ppmであってもよく、1~100,000ppmであってもよく、10~100,000ppmであってもよい。当該合計の濃度は、天秤等で秤量可能である。
The content of the lactic acid bacteria cell preparation contained in the growth inhibitor or bactericide is not particularly limited, but may be, for example, 1×10 3 to 1×10 12 cfu/mL, or 1×10 5 to 1×10 cfu/mL. It may be x10 12 cfu/mL, or may be from 1 x 10 7 to 1 x 10 12 cfu/mL. The colony-forming unit can be determined by an agar plate culture method. The total concentration of the lactic acid bacteria cell preparation contained in the growth inhibitor or disinfectant is not particularly limited, and may be 0.1 to 100,000 ppm, or 1 to 100,000 ppm. , from 10 to 100,000 ppm. The total concentration can be weighed with a balance or the like.
本発明の一実施形態に係る歯周病の原因菌の増殖抑制または殺菌方法は、ラクトバチルス・プランタラムの菌体もしくは菌体培養物またはこれらの抽出物を歯周病の原因菌に接触させることを含む。ラクトバチルス・プランタラムの菌体調製物と歯周病の原因菌とを接触させる方法は特に限定されず、例えば歯周病の原因菌が存在する環境にラクトバチルス・プランタラムの菌体調製物を添加してもよく、歯周病の原因菌が存在する物体をラクトバチルス・プランタラムの菌体調製物を含む液体に浸漬してもよく、歯周病の原因菌が感染した宿主にラクトバチルス・プランタラムの菌体調製物を含む組成物を経口投与してもよい。ラクトバチルス・プランタラムの菌体調製物は、歯周病の原因菌の増殖抑制剤または殺菌剤の形態で供給されてもよい。
A method for inhibiting or sterilizing the growth of periodontal disease-causing bacteria according to one embodiment of the present invention comprises contacting Lactobacillus plantarum bacteria or bacterial cell cultures or extracts thereof with periodontal disease-causing bacteria. Including. The method of contacting the bacterial cell preparation of Lactobacillus plantarum with the causative bacteria of periodontal disease is not particularly limited. may be added, an object in which periodontal disease-causing bacteria are present may be immersed in a liquid containing a bacterial cell preparation of Lactobacillus plantarum, and a host infected with periodontal disease-causing bacteria may be lacto Compositions containing the bacterial cell preparation of Bacillus plantarum may be administered orally. The bacterial cell preparation of Lactobacillus plantarum may be supplied in the form of a periodontal disease-causing bacteria growth inhibitor or bactericide.
本発明の一実施形態は、歯周病の原因菌の増殖抑制剤または殺菌剤の製造におけるラクトバチルス・プランタラムの菌体もしくは菌体培養物またはこれらの抽出物の使用である。本発明の一実施形態は、歯周病の原因菌の増殖抑制または殺菌のためのラクトバチルス・プランタラムの菌体もしくは菌体培養物またはこれらの抽出物の使用である。
One embodiment of the present invention is the use of Lactobacillus plantarum cells or cell cultures or extracts thereof in the production of growth inhibitors or fungicides for periodontal disease-causing bacteria. One embodiment of the present invention is the use of Lactobacillus plantarum cells or cell cultures or extracts thereof for growth inhibition or sterilization of periodontal disease-causing bacteria.
以下、実施例を挙げて本発明をより詳細に説明するが、本発明はこれらの実施例に限定されるものではない。
The present invention will be described in more detail below with reference to examples, but the present invention is not limited to these examples.
[実験1:NITE BP-03198の分離および同定]
分離源(イカ塩辛)を滅菌水と共に摩砕した。摩砕液を適宜希釈して1/2MRS液体培地に添加し、集積培養した。集積培養液を炭酸カルシウム含有のMRS寒天培地に塗抹し、ハローを形成した微生物を分離した。以下、この分離株を分離株Aという。過酸化水素に分離株Aの培養液を懸濁したところ、気泡が発生しなかった。分離株Aは、カタラーゼ活性を有しないことから、乳酸菌であることが確認された。 [Experiment 1: Separation and identification of NITE BP-03198]
The isolate (squid salted fish) was ground with sterile water. The homogenate was appropriately diluted and added to 1/2 MRS liquid medium for enrichment culture. The enriched culture was smeared on a calcium carbonate-containing MRS agar medium to isolate microorganisms that formed halos. Hereinafter, this isolate will be referred to as isolate A. Suspension of isolate A cultures in hydrogen peroxide did not generate bubbles. Isolate A was confirmed to be a lactic acid bacterium because it did not have catalase activity.
分離源(イカ塩辛)を滅菌水と共に摩砕した。摩砕液を適宜希釈して1/2MRS液体培地に添加し、集積培養した。集積培養液を炭酸カルシウム含有のMRS寒天培地に塗抹し、ハローを形成した微生物を分離した。以下、この分離株を分離株Aという。過酸化水素に分離株Aの培養液を懸濁したところ、気泡が発生しなかった。分離株Aは、カタラーゼ活性を有しないことから、乳酸菌であることが確認された。 [Experiment 1: Separation and identification of NITE BP-03198]
The isolate (squid salted fish) was ground with sterile water. The homogenate was appropriately diluted and added to 1/2 MRS liquid medium for enrichment culture. The enriched culture was smeared on a calcium carbonate-containing MRS agar medium to isolate microorganisms that formed halos. Hereinafter, this isolate will be referred to as isolate A. Suspension of isolate A cultures in hydrogen peroxide did not generate bubbles. Isolate A was confirmed to be a lactic acid bacterium because it did not have catalase activity.
16S rRNA遺伝子解析、形態観察および生理・生化学的性状試験によって、分離株Aを同定した。
(1)16S rRNA遺伝子解析
分離株AからゲノムDNAを抽出し、得られたゲノムDNAを鋳型として、クローニング用フォワードプライマー9Fおよびクローニング用リバースプライマー1510R(中川恭好他:遺伝子解析法 16S rRNA遺伝子の塩基配列決定法、日本放線菌学会編、放線菌の分類と同定、88-117pp.日本学会事務センター、2001)を用いて16S rRNA遺伝子のPCR増幅を行った。PCR増幅はTks Gflex DNA ポリメラーゼ(タカラバイオ社製)を用いて行い、PCR後の増幅産物を精製した。 Isolate A was identified by 16S rRNA gene analysis, morphological observation, and physiological and biochemical characterization tests.
(1) 16S rRNA gene analysis Genomic DNA was extracted from the isolate A, and the resulting genomic DNA was used as a template for cloning forward primer 9F and cloning reverse primer 1510R (Yoshiyoshi Nakagawa et al.: Genetic analysis method of 16S rRNA gene. PCR amplification of the 16S rRNA gene was performed using a nucleotide sequencing method, Actinomycetes Society of Japan, Classification and Identification of Actinomycetes, 88-117 pp. Japan Society Office, 2001). PCR amplification was performed using Tks Gflex DNA polymerase (manufactured by Takara Bio Inc.), and the amplified product after PCR was purified.
(1)16S rRNA遺伝子解析
分離株AからゲノムDNAを抽出し、得られたゲノムDNAを鋳型として、クローニング用フォワードプライマー9Fおよびクローニング用リバースプライマー1510R(中川恭好他:遺伝子解析法 16S rRNA遺伝子の塩基配列決定法、日本放線菌学会編、放線菌の分類と同定、88-117pp.日本学会事務センター、2001)を用いて16S rRNA遺伝子のPCR増幅を行った。PCR増幅はTks Gflex DNA ポリメラーゼ(タカラバイオ社製)を用いて行い、PCR後の増幅産物を精製した。 Isolate A was identified by 16S rRNA gene analysis, morphological observation, and physiological and biochemical characterization tests.
(1) 16S rRNA gene analysis Genomic DNA was extracted from the isolate A, and the resulting genomic DNA was used as a template for cloning forward primer 9F and cloning reverse primer 1510R (Yoshiyoshi Nakagawa et al.: Genetic analysis method of 16S rRNA gene. PCR amplification of the 16S rRNA gene was performed using a nucleotide sequencing method, Actinomycetes Society of Japan, Classification and Identification of Actinomycetes, 88-117 pp. Japan Society Office, 2001). PCR amplification was performed using Tks Gflex DNA polymerase (manufactured by Takara Bio Inc.), and the amplified product after PCR was purified.
精製したPCR後の増幅産物を用いてサイクルシーケンス反応を行った。サイクルシーケンス反応は、BigDye Terminator v3.1 Cycle Sequencing Kitを用いて行った。得られた反応液を精製し、精製液をDNAシーケンス解析(3130xl DNA Analyzer)に供して、分離株Aから抽出した鋳型DNAの16S rRNA遺伝子の塩基配列を決定した。シークエンス解析用プライマーとしては、9F、515F、1099F、536R、926R、1510R(中川恭好他:遺伝子解析法 16S rRNA遺伝子の塩基配列決定法、日本放線菌学会編、放線菌の分類と同定、88-117pp.日本学会事務センター、2001)を用いた。
A cycle sequencing reaction was performed using the purified amplified product after PCR. The cycle sequencing reaction was performed using BigDye Terminator v3.1 Cycle Sequencing Kit. The resulting reaction solution was purified, and the purified solution was subjected to DNA sequence analysis (3130xl DNA Analyzer) to determine the base sequence of the 16S rRNA gene of the template DNA extracted from isolate A. Sequence analysis primers include 9F, 515F, 1099F, 536R, 926R, and 1510R (Yoshiyoshi Nakagawa et al.: Gene analysis method 16S rRNA gene sequencing method, Actinomycetes Society of Japan, Classification and Identification of Actinomycetes, 88 -117 pp. Japan Society Administrative Center, 2001) was used.
分離株Aの16S rRNA遺伝子の塩基配列を微生物同定システム「ENKI」(テクノスルガ・ラボ社製)を用いて、微生物同定データベースDB-BA15.0(テクノスルガ・ラボ社製)、国際塩基配列データベース(DDBJ/ENA(EMBL)/GenBank)に対してBLAST相同性検索を行った。分離株Aの16S rRNA遺伝子の塩基配列は、Lactobacillus pentosus(JCM1558)の16S rRNA遺伝子の塩基配列に対して同一性99.87%、Lactobacillus plantarum subsp.plantarum(JCM1149)の16S rRNA遺伝子の塩基配列に対して同一性99.87%、Lactobacillus paraplantarum(DSM10667)の16S rRNA遺伝子の塩基配列に対して同一性99.73%を示した。しかし、分離株Aの16S rRNA遺伝子の塩基配列と完全に一致する16S rRNA遺伝子を持つ微生物は存在しなかった。
Using the microorganism identification system "ENKI" (manufactured by Techno Suruga Lab), the base sequence of the 16S rRNA gene of isolate A was identified as a microorganism identification database DB-BA15.0 (manufactured by Techno Suruga Lab), an international base sequence database A BLAST homology search was performed against (DDBJ/ENA(EMBL)/GenBank). The nucleotide sequence of the 16S rRNA gene of isolate A has 99.87% identity to the nucleotide sequence of the 16S rRNA gene of Lactobacillus pentosus (JCM1558), Lactobacillus plantarum subsp. It showed 99.87% identity to the nucleotide sequence of the 16S rRNA gene of Lactobacillus (JCM1149) and 99.73% identity to the nucleotide sequence of the 16S rRNA gene of Lactobacillus paraplantarum (DSM10667). However, there was no microorganism with a 16S rRNA gene that completely matched the base sequence of the 16S rRNA gene of isolate A.
(2)形態観察および生理・生化学的性状試験
MRS寒天培地に分離菌Aを塗布し、温度30℃で48時間好気培養し、以下の方法で細胞形態、グラム染色性、運動性およびコロニー形態を観察した。細胞形態は、光学顕微鏡BX50F4(オリンパス社製)によって観察した。グラム染色ではフェイバーG「ニッスイ」(日水製薬社製)を用いた。コロニー形態は、実体顕微鏡SMZ800N(ニコン社製)によって観察した。Barrow&Feltham(Cowan and Steel’s Manual for the Identification of Medical Bacteria,3rd ed.Cambridge:Cambridge University Press;1993.)に記載の方法に基づき、カタラーゼ反応、オキシダーゼ反応、ブドウ糖からの酸/ガス産生およびブドウ糖の酸化/発酵(O/F)について試験を行った。API50CHBキット(bioMerieux社製、フランス)を用いて、細菌の生理・生化学的性状反応を調べた。 (2) Morphological Observation and Physiological/Biochemical Property Test The isolate A was applied to an MRS agar medium and aerobically cultured at a temperature of 30° C. for 48 hours. Morphology was observed. Cell morphology was observed with an optical microscope BX50F4 (manufactured by Olympus). For Gram staining, Favor G "Nissui" (manufactured by Nissui Pharmaceutical Co., Ltd.) was used. Colony morphology was observed with a stereoscopic microscope SMZ800N (manufactured by Nikon Corporation). Based on the method described in Barrow & Feltham (Cowan and Steel's Manual for the Identification of Medical Bacteria, 3rd ed. Cambridge: Cambridge University Press; 1993.), catalase reaction, oxidase reaction, production gas from glucose and acid / Testing was done for oxidation/fermentation (O/F). The API50CHB kit (manufactured by bioMerieux, France) was used to examine the physiological and biochemical properties of the bacteria.
MRS寒天培地に分離菌Aを塗布し、温度30℃で48時間好気培養し、以下の方法で細胞形態、グラム染色性、運動性およびコロニー形態を観察した。細胞形態は、光学顕微鏡BX50F4(オリンパス社製)によって観察した。グラム染色ではフェイバーG「ニッスイ」(日水製薬社製)を用いた。コロニー形態は、実体顕微鏡SMZ800N(ニコン社製)によって観察した。Barrow&Feltham(Cowan and Steel’s Manual for the Identification of Medical Bacteria,3rd ed.Cambridge:Cambridge University Press;1993.)に記載の方法に基づき、カタラーゼ反応、オキシダーゼ反応、ブドウ糖からの酸/ガス産生およびブドウ糖の酸化/発酵(O/F)について試験を行った。API50CHBキット(bioMerieux社製、フランス)を用いて、細菌の生理・生化学的性状反応を調べた。 (2) Morphological Observation and Physiological/Biochemical Property Test The isolate A was applied to an MRS agar medium and aerobically cultured at a temperature of 30° C. for 48 hours. Morphology was observed. Cell morphology was observed with an optical microscope BX50F4 (manufactured by Olympus). For Gram staining, Favor G "Nissui" (manufactured by Nissui Pharmaceutical Co., Ltd.) was used. Colony morphology was observed with a stereoscopic microscope SMZ800N (manufactured by Nikon Corporation). Based on the method described in Barrow & Feltham (Cowan and Steel's Manual for the Identification of Medical Bacteria, 3rd ed. Cambridge: Cambridge University Press; 1993.), catalase reaction, oxidase reaction, production gas from glucose and acid / Testing was done for oxidation/fermentation (O/F). The API50CHB kit (manufactured by bioMerieux, France) was used to examine the physiological and biochemical properties of the bacteria.
図1の(A)に示すように、分離株Aは円形のコロニーを形成した。図1の(B)に示すように、分離株Aはグラム染色性が陽性であった。分離株Aの生理・生化学的性状試験および発酵性試験の結果を表1および表2に示す。分離株Aは運動性を示さないグラム陽性の桿菌で、芽胞を形成せず、カタラーゼ反応およびオキシダーゼ反応は陰性を示し、グルコースを発酵した。これらの性状は、16S rDNA部分塩基配列解析の結果、帰属の可能性が示されたLactobacillus属の性状と一致した。APIキットを用いて行った発酵性試験の結果、分離株Aはガラクトース、フラクトースおよびメレチトース等を発酵し、グリセロール、D-キシロース等を発酵しなかった。分離株Aは、アルギニンジヒドロラーゼ活性を示さず、15℃で生育した。これらの性状は、16S rDNA部分塩基配列解析の結果、帰属が示唆されたL.pentosusおよびL.plantarumのうち、グリセロールおよびD-キシロースの発酵を示さない点がL.pentosusと異なり、L.plantarumの性状と一致した。従って、分離株AはLactobacillus plantarumに属する新規分離株であることがわかった。分離株AをNITE BP-03198として国際寄託した。
As shown in Figure 1 (A), isolate A formed circular colonies. As shown in FIG. 1(B), isolate A was positive for Gram staining. Tables 1 and 2 show the results of physiological/biochemical property tests and fermentability tests of isolate A. Isolate A was a non-motile Gram-positive bacillus, did not form spores, was negative in catalase and oxidase reactions, and fermented glucose. These properties were consistent with those of the genus Lactobacillus, for which the possibility of attribution was shown as a result of 16S rDNA partial nucleotide sequence analysis. As a result of a fermentability test conducted using an API kit, isolate A fermented galactose, fructose, melezitose, etc., but did not ferment glycerol, D-xylose, etc. Isolate A showed no arginine dihydrolase activity and grew at 15°C. These properties were attributed to L. cerevisiae, whose attribution was suggested as a result of 16S rDNA partial nucleotide sequence analysis. pentosus and L. Among L. plantarum, L. plantarum shows no fermentation of glycerol and D-xylose. Unlike L. pentosus, L. It matched the properties of plantarum. Therefore, isolate A was found to be a novel isolate belonging to Lactobacillus plantarum. The isolate A was internationally deposited as NITE BP-03198.
[実験2:NITE BP-03199の分離および同定]
分離源として、レンブを用いた以外は、実験1と同じ方法により、分離株Bを分離した。分離株Bの同定を実験1と同じ方法によって行なった。 [Experiment 2: Separation and identification of NITE BP-03199]
Isolate B was isolated by the same method as Experiment 1, except that Lembu was used as the isolation source. Identification of isolate B was performed by the same method as in Experiment 1.
分離源として、レンブを用いた以外は、実験1と同じ方法により、分離株Bを分離した。分離株Bの同定を実験1と同じ方法によって行なった。 [Experiment 2: Separation and identification of NITE BP-03199]
Isolate B was isolated by the same method as Experiment 1, except that Lembu was used as the isolation source. Identification of isolate B was performed by the same method as in Experiment 1.
分離株Bの16S rRNA遺伝子の塩基配列は、Lactobacillus pentosus(JCM1558)の16S rRNA遺伝子の塩基配列に対して同一性100.0%、Lactobacillus plantarum subsp.plantarum(JCM1149)の16S rRNA遺伝子の塩基配列に対して同一性100.0%、Lactobacillus paraplantarum(DSM10667)の16S rRNA遺伝子の塩基配列に対して同一性99.80%を示した。
The base sequence of the 16S rRNA gene of isolate B has 100.0% identity to the base sequence of the 16S rRNA gene of Lactobacillus pentosus (JCM1558), Lactobacillus plantarum subsp. It showed 100.0% identity to the nucleotide sequence of the 16S rRNA gene of Lactobacillus (JCM1149) and 99.80% identity to the nucleotide sequence of the 16S rRNA gene of Lactobacillus paraplantarum (DSM10667).
図2の(A)に示すように、分離株Bは円形のコロニーを形成した。図2の(B)に示すように、分離株Bはグラム染色性が陽性であった。分離株Bの生理・生化学的性状試験および発酵性試験の結果を表3および表4に示す。分離株Bは運動性を示さないグラム陽性の桿菌で、芽胞を形成せず、カタラーゼ反応およびオキシダーゼ反応は陰性を示し、グルコースを発酵した。これらの性状は、16S rDNA部分塩基配列解析の結果、帰属の可能性が示されたLactobacillus属の性状と一致した。APIキットを用いて行った発酵性試験の結果、分離株Bはガラクトース、フラクトース、α-メチル-D-マンノシドおよびメレチトース等を発酵し、グリセロール、D-キシロース等を発酵しなかった。分離株Bは、アルギニンジヒドロラーゼ活性を示さず、15℃で生育した。これらの性状は、16S rDNA部分塩基配列解析の結果、帰属が示唆されたL.pentosusおよびL.plantarumのうち、グリセロールおよびD-キシロースの発酵を示さない点がL.pentosusと異なり、L.plantarumの性状と一致した。従って、分離株BはLactobacillus plantarumに属する新規分離株であることがわかった。分離株BをNITE BP-03199として国際寄託した。
As shown in Figure 2 (A), isolate B formed circular colonies. As shown in FIG. 2B, isolate B was positive for Gram staining. Tables 3 and 4 show the results of physiological and biochemical property tests and fermentability tests of isolate B. Isolate B was a non-motile Gram-positive bacillus, did not form spores, was negative in catalase and oxidase reactions, and fermented glucose. These properties were consistent with those of the genus Lactobacillus, for which the possibility of attribution was shown as a result of 16S rDNA partial nucleotide sequence analysis. As a result of a fermentability test conducted using an API kit, isolate B fermented galactose, fructose, α-methyl-D-mannoside and melezitose, etc., but did not ferment glycerol, D-xylose, etc. Isolate B showed no arginine dihydrolase activity and grew at 15°C. These properties were attributed to L. cerevisiae, whose attribution was suggested as a result of 16S rDNA partial nucleotide sequence analysis. pentosus and L. Among L. plantarum, L. plantarum shows no fermentation of glycerol and D-xylose. Unlike L. pentosus, L. It matched the properties of plantarum. Therefore, isolate B was found to be a novel isolate belonging to Lactobacillus plantarum. Isolate B was internationally deposited as NITE BP-03199.
[実験3:NITE BP-03200の分離および同定]
分離源として、アダンを用いた以外は、実験1と同じ方法により、分離株Cを分離した。分離株Cの同定を実験1と同じ方法によって行なった。 [Experiment 3: Separation and identification of NITE BP-03200]
Isolate C was isolated by the same method as in Experiment 1, except that pandanus was used as the isolation source. Identification of isolate C was performed by the same method as in Experiment 1.
分離源として、アダンを用いた以外は、実験1と同じ方法により、分離株Cを分離した。分離株Cの同定を実験1と同じ方法によって行なった。 [Experiment 3: Separation and identification of NITE BP-03200]
Isolate C was isolated by the same method as in Experiment 1, except that pandanus was used as the isolation source. Identification of isolate C was performed by the same method as in Experiment 1.
分離株Cの16S rRNA遺伝子の塩基配列は、Lactobacillus pentosus(JCM1558)の16S rRNA遺伝子の塩基配列に対して同一性99.87%、Lactobacillus plantarum subsp.plantarum(JCM1149)の16S rRNA遺伝子の塩基配列に対して同一性99.87%、Lactobacillus paraplantarum(DSM10667)の16S rRNA遺伝子の塩基配列に対して同一性99.66%を示した。しかし、分離株Cの16S rRNA遺伝子の塩基配列と完全に一致する16S rRNA遺伝子を持つ微生物は存在しなかった。
The base sequence of the 16S rRNA gene of isolate C has 99.87% identity to the base sequence of the 16S rRNA gene of Lactobacillus pentosus (JCM1558), Lactobacillus plantarum subsp. It showed 99.87% identity to the nucleotide sequence of the 16S rRNA gene of Lactobacillus (JCM1149) and 99.66% identity to the nucleotide sequence of the 16S rRNA gene of Lactobacillus paraplantarum (DSM10667). However, there was no microorganism with a 16S rRNA gene that completely matched the base sequence of the isolate C 16S rRNA gene.
図3の(A)に示すように、分離株Cは円形のコロニーを形成した。図3の(B)に示すように、分離株Cはグラム染色性が陽性であった。分離株Cの生理・生化学的性状試験および発酵性試験の結果を表5および表6に示す。分離株Cは運動性を示さないグラム陽性の桿菌で、芽胞を形成せず、カタラーゼ反応およびオキシダーゼ反応は陰性を示し、グルコースを発酵した。これらの性状は、16S rDNA部分塩基配列解析の結果、帰属の可能性が示されたLactobacillus属の性状と一致した。APIキットを用いて行った発酵性試験の結果、分離株Cはガラクトース、フラクトース、α-メチル-D-マンノシドおよびメレチトース等を発酵し、グリセロール、D-キシロース等を発酵しなかった。分離株Cは、アルギニンジヒドロラーゼ活性を示さず、15℃で生育した。これらの性状は、16S rDNA部分塩基配列解析の結果、近縁と示されたL.pentosusおよびL.plantarumのうち、グリセロールおよびD-キシロースの発酵を示さない点がL.pentosusと異なり、L.plantarumの性状と一致した。従って、分離株CはLactobacillus plantarumに属する新規分離株であることがわかった。分離株CをNITE BP-03200として国際寄託した。
As shown in Figure 3 (A), isolate C formed circular colonies. As shown in FIG. 3B, isolate C was positive for Gram staining. Tables 5 and 6 show the results of physiological and biochemical property tests and fermentability tests of isolate C. Isolate C was a non-motile Gram-positive bacillus, did not form spores, was negative in catalase and oxidase reactions, and fermented glucose. These properties were consistent with those of the genus Lactobacillus, for which the possibility of attribution was shown as a result of 16S rDNA partial nucleotide sequence analysis. As a result of a fermentability test conducted using an API kit, isolate C fermented galactose, fructose, α-methyl-D-mannoside and melezitose, etc., but did not ferment glycerol, D-xylose, etc. Isolate C showed no arginine dihydrolase activity and grew at 15°C. These properties were shown to be closely related as a result of 16S rDNA partial nucleotide sequence analysis. pentosus and L. Among L. plantarum, L. plantarum shows no fermentation of glycerol and D-xylose. Unlike L. pentosus, L. It matched the properties of plantarum. Therefore, isolate C was found to be a novel isolate belonging to Lactobacillus plantarum. Isolate C was internationally deposited as NITE BP-03200.
[実験4:NITE BP-03201の分離および同定]
分離源として、ギランイヌビワを用いた以外は、実験1と同じ方法により分離株Dを分離した。分離株Dの同定を実験1と同じ方法によって行なった。 [Experiment 4: Separation and identification of NITE BP-03201]
Isolate D was isolated by the same method as in Experiment 1, except that G. japonica was used as the isolation source. Identification of isolate D was performed by the same method as in Experiment 1.
分離源として、ギランイヌビワを用いた以外は、実験1と同じ方法により分離株Dを分離した。分離株Dの同定を実験1と同じ方法によって行なった。 [Experiment 4: Separation and identification of NITE BP-03201]
Isolate D was isolated by the same method as in Experiment 1, except that G. japonica was used as the isolation source. Identification of isolate D was performed by the same method as in Experiment 1.
分離株Dの16S rRNA遺伝子の塩基配列は、Lactobacillus pentosus(JCM1558)の16S rRNA遺伝子の塩基配列に対して同一性99.93%、Lactobacillus plantarum subsp.plantarum(JCM1149)の16S rRNA遺伝子の塩基配列に対して同一性99.93%、Lactobacillus paraplantarum(DSM10667)の16S rRNA遺伝子の塩基配列に対して同一性99.73%を示した。しかし、分離株Dの16S rRNA遺伝子の塩基配列と完全に一致する16S rRNA遺伝子を持つ微生物は存在しなかった。
The base sequence of the 16S rRNA gene of isolate D has 99.93% identity to the base sequence of the 16S rRNA gene of Lactobacillus pentosus (JCM1558), Lactobacillus plantarum subsp. It showed 99.93% identity to the nucleotide sequence of the 16S rRNA gene of Lactobacillus (JCM1149) and 99.73% identity to the nucleotide sequence of the 16S rRNA gene of Lactobacillus paraplantarum (DSM10667). However, no microorganism with a 16S rRNA gene that completely matches the base sequence of the 16S rRNA gene of isolate D was found.
図4の(A)に示すように、分離株Dは円形のコロニーを形成した。図4の(B)に示すように、分離株Dはグラム染色性が陽性であった。分離株Dの生理・生化学的性状試験および発酵性試験の結果を表5および表6に示す。分離株Dは運動性を示さないグラム陽性の桿菌で、芽胞を形成せず、カタラーゼ反応およびオキシダーゼ反応は陰性を示し、グルコースを発酵した。これらの性状は、16S rDNA部分塩基配列解析の結果、帰属の可能性が示されたLactobacillus属の性状と一致した。APIキットを用いて行った発酵性試験の結果、分離株Dはガラクトース、フラクトースおよびメレチトース等を発酵し、グリセロール、D-キシロース等を発酵しなかった。分離株Dは、アルギニンジヒドロラーゼ活性を示さず、15℃で生育した。これらの性状は、16S rDNA部分塩基配列解析の結果、帰属が示唆されたL.pentosusおよびL.plantarumのうち、グリセロールおよびD-キシロースの発酵を示さない点がL.pentosusと異なり、L.plantarumの性状と一致した。従って、分離株DはLactobacillus plantarumに属する新規分離株であることがわかった。分離株DをNITE BP-03201として国際寄託した。
As shown in Figure 4 (A), isolate D formed circular colonies. As shown in FIG. 4B, isolate D was positive for Gram staining. Tables 5 and 6 show the results of physiological/biochemical property tests and fermentability tests of isolate D. Isolate D was a non-motile Gram-positive bacillus, did not form spores, was negative in catalase and oxidase reactions, and fermented glucose. These properties were consistent with those of the genus Lactobacillus, for which the possibility of attribution was shown as a result of 16S rDNA partial nucleotide sequence analysis. As a result of a fermentability test conducted using an API kit, isolate D fermented galactose, fructose and melezitose, etc., but did not ferment glycerol, D-xylose, etc. Isolate D showed no arginine dihydrolase activity and grew at 15°C. These properties were attributed to L. cerevisiae, whose attribution was suggested as a result of 16S rDNA partial nucleotide sequence analysis. pentosus and L. Among L. plantarum, L. plantarum shows no fermentation of glycerol and D-xylose. Unlike L. pentosus, L. It matched the properties of plantarum. Therefore, isolate D was found to be a novel isolate belonging to Lactobacillus plantarum. Isolate D was internationally deposited as NITE BP-03201.
[実験5:NITE BP-03202の分離および同定]
分離源として、マツボックリを用いた以外は、実験1と同じ方法により分離株Eを分離した。分離株Eの同定を実験1と同じ方法によって行なった。 [Experiment 5: Separation and identification of NITE BP-03202]
Isolate E was isolated by the same method as in Experiment 1, except that Pinus chinensis was used as the isolation source. Identification of isolate E was performed by the same method as in Experiment 1.
分離源として、マツボックリを用いた以外は、実験1と同じ方法により分離株Eを分離した。分離株Eの同定を実験1と同じ方法によって行なった。 [Experiment 5: Separation and identification of NITE BP-03202]
Isolate E was isolated by the same method as in Experiment 1, except that Pinus chinensis was used as the isolation source. Identification of isolate E was performed by the same method as in Experiment 1.
分離株Eの16S rRNA遺伝子の塩基配列は、Lactobacillus pentosus(JCM1558)の16S rRNA遺伝子の塩基配列に対して同一性99.93%、Lactobacillus plantarum subsp.plantarum(JCM1149)の16S rRNA遺伝子の塩基配列に対して同一性99.93%、Lactobacillus paraplantarum(DSM10667)の16S rRNA遺伝子の塩基配列に対して同一性99.73%を示した。しかし、分離株Eの16S rRNA遺伝子の塩基配列と完全に一致する16S rRNA遺伝子を持つ微生物は存在しなかった。
The nucleotide sequence of the 16S rRNA gene of isolate E has 99.93% identity to the nucleotide sequence of the 16S rRNA gene of Lactobacillus pentosus (JCM1558), Lactobacillus plantarum subsp. It showed 99.93% identity to the nucleotide sequence of the 16S rRNA gene of Lactobacillus (JCM1149) and 99.73% identity to the nucleotide sequence of the 16S rRNA gene of Lactobacillus paraplantarum (DSM10667). However, no microorganism with a 16S rRNA gene that completely matches the base sequence of the isolate E 16S rRNA gene was found.
図5の(A)に示すように、分離株Eは円形のコロニーを形成した。図5の(B)に示すように、分離株Eはグラム染色性が陽性であった。分離株Eの生理・生化学的性状試験および発酵性試験の結果を表9および表10に示す。分離株Eは運動性を示さないグラム陽性の桿菌で、芽胞を形成せず、カタラーゼ反応およびオキシダーゼ反応は陰性を示し、グルコースを発酵した。これらの性状は、16S rDNA部分塩基配列解析の結果、帰属の可能性が示されたLactobacillus属の性状と一致した。APIキットを用いて行った発酵性試験の結果、分離株Eはガラクトース、フラクトース、α-メチル-D-マンノシドおよびメレチトース等を発酵し、グリセロール、D-キシロース等を発酵しなかった。分離株Eは、アルギニンジヒドロラーゼ活性を示さず、15℃で生育した。これらの性状は、16S rDNA部分塩基配列解析の結果、帰属が示唆されたL.pentosusおよびL.plantarumのうち、グリセロールおよびD-キシロースの発酵を示さない点がL.pentosusと異なり、L.plantarumの性状と一致した。従って、分離株EはLactobacillus plantarumに属する新規分離株であることがわかった。分離株EをNITE BP-03202として国際寄託した。
As shown in Figure 5 (A), isolate E formed circular colonies. As shown in FIG. 5B, isolate E was positive for Gram staining. Tables 9 and 10 show the results of physiological and biochemical property tests and fermentability tests of isolate E. Isolate E was a non-motile Gram-positive bacillus, did not form spores, was negative in catalase and oxidase reactions, and fermented glucose. These properties were consistent with those of the genus Lactobacillus, for which the possibility of attribution was shown as a result of 16S rDNA partial nucleotide sequence analysis. As a result of a fermentability test conducted using an API kit, isolate E fermented galactose, fructose, α-methyl-D-mannoside and melezitose, etc., but did not ferment glycerol, D-xylose, etc. Isolate E showed no arginine dihydrolase activity and grew at 15°C. These properties were attributed to L. cerevisiae, whose attribution was suggested as a result of 16S rDNA partial nucleotide sequence analysis. pentosus and L. Among L. plantarum, L. plantarum shows no fermentation of glycerol and D-xylose. Unlike L. pentosus, L. It matched the properties of plantarum. Therefore, isolate E was found to be a novel isolate belonging to Lactobacillus plantarum. The isolate E was internationally deposited as NITE BP-03202.
[実験6:歯周病の原因菌に対するラクトバチルス・プランタラムの抗菌活性評価試験]
NITE BP-03198、NITE BP-03199、NITE BP-03200、NITE BP-03201およびNITE BP-03202の菌体調製物が、歯周病の原因菌の増殖を抑制するかを検証した。 [Experiment 6: Antibacterial activity evaluation test of Lactobacillus plantarum against bacteria causing periodontal disease]
It was verified whether the cell preparations of NITE BP-03198, NITE BP-03199, NITE BP-03200, NITE BP-03201 and NITE BP-03202 inhibit the growth of periodontal disease-causing bacteria.
NITE BP-03198、NITE BP-03199、NITE BP-03200、NITE BP-03201およびNITE BP-03202の菌体調製物が、歯周病の原因菌の増殖を抑制するかを検証した。 [Experiment 6: Antibacterial activity evaluation test of Lactobacillus plantarum against bacteria causing periodontal disease]
It was verified whether the cell preparations of NITE BP-03198, NITE BP-03199, NITE BP-03200, NITE BP-03201 and NITE BP-03202 inhibit the growth of periodontal disease-causing bacteria.
図6を参照して実験方法を説明する。表11に記載の培地および培養条件に従って、歯周病の原因菌(P.g.菌、T.f.菌およびT.d.菌)を前培養した。歯周病の原因菌をGAM brothに懸濁し、McFarland No.0.5(約1×108~2×108cfu/mL)となるように調整した。これをさらに10倍希釈して歯周病の原因菌の菌液11(約1×107~2×107cfu/mL)とした。100μLの歯周病菌の菌液11を測定用寒天培地12に滴下し、コンラージ棒で均一に塗布した。寒天培地の表面が乾いたら、10μLのラクトバチルス・プランタラムの菌体調製物13を滴下し、35℃で嫌気性環境下で培養した。P.g.菌は5日間、T.f.菌は7日間、T.d.菌は4日間培養した。ラクトバチルス・プランタラムの菌体調製物が歯周病の原因菌に対する抗菌活性を有するとき、生育阻止円14が形成される。ラクトバチルス・プランタラムの菌体調製物は、NITE BP-03198、NITE BP-03199、NITE BP-03200、NITE BP-03201およびNITE BP-03202のいずれかの乳酸菌をMRS Brothで温度30℃で培養し、遠心分離によって菌体を沈殿させた培養上清(菌体培養物)を用いた。P.g.菌、T.f.菌およびT.d.菌に対する抗菌活性の結果を表12、13および14にそれぞれ示す。ネガティブコントロールとして乳酸菌用培地(MRS Broth)を用いた。ポジティブコントロールとして、メロペネム10μg/6mmφを含むセンシ・ディスク「MEPM」(日本ベクトン・ディッキンソン社製)またはキノロン系抗菌剤レボフロキサシン10μg/6mmφを含むセンシディスク「LVFX」(日本ベクトン・ディッキンソン社製)を用いた。ATCC-11454は、ナイシンAを産生する乳酸菌(Lactococcus subsp.lactis)である。ナイシンA産生株は、ラクトバチルス・プランタラムと同じ方法で培養し、培養上清を調整した。
The experimental method will be described with reference to FIG. According to the medium and culture conditions described in Table 11, periodontal disease-causing bacteria (Pg, Tf and Td) were precultured. The causative bacteria of periodontal disease were suspended in GAM broth, and McFarland No. 0.5 (approximately 1×10 8 to 2×10 8 cfu/mL). This was further diluted 10-fold to obtain a periodontal disease-causing bacterial solution 11 (about 1×10 7 to 2×10 7 cfu/mL). 100 μL of periodontal disease bacterium liquid 11 was dropped on an agar medium 12 for measurement, and was evenly applied with a Conlarge stick. After the surface of the agar medium was dry, 10 μL of the cell preparation 13 of Lactobacillus plantarum was dropped and cultured at 35° C. in an anaerobic environment. P. g. The fungus was killed for 5 days, T. f. The fungus was killed for 7 days, T. d. The fungus was cultured for 4 days. Growth inhibition circles 14 are formed when the bacterial cell preparation of Lactobacillus plantarum has antibacterial activity against periodontal disease-causing bacteria. The bacterial cell preparation of Lactobacillus plantarum is obtained by culturing any of NITE BP-03198, NITE BP-03199, NITE BP-03200, NITE BP-03201 and NITE BP-03202 in MRS Broth at a temperature of 30 ° C. Then, the culture supernatant (cell culture) obtained by sedimenting the cells by centrifugation was used. P. g. fungus, T. f. fungi and T. d. The results of antibacterial activity against fungi are shown in Tables 12, 13 and 14, respectively. A medium for lactic acid bacteria (MRS Broth) was used as a negative control. As a positive control, use Sensidisc "MEPM" (manufactured by Nippon Becton Dickinson) containing meropenem 10 μg/6 mmφ or Sensidisc "LVFX" (manufactured by Nippon Becton Dickinson) containing 10 μg/6 mmφ quinolone antibacterial agent levofloxacin. board. ATCC-11454 is a nisin-A producing lactic acid bacterium (Lactococcus subsp. lactis). The nisin A-producing strain was cultured in the same manner as Lactobacillus plantarum, and the culture supernatant was prepared.
NITE BP-03198、NITE BP-03199、NITE BP-03200、NITE BP-03201およびNITE BP-03202の菌体培養物はいずれも、P.g.菌、T.f.菌およびT.d.菌の生育培地の全てに生育阻止円を形成させた。ラクトバチルス・プランタラムの菌体培養物はいずれも、P.g.菌、T.f.菌およびT.d.菌の増殖を抑制できることが示された。一方、ナイシンA産生株の培養上清は、T.d.菌の増殖を抑制したが、P.g.菌およびT.f.菌の増殖を抑制することができなかった。
All of the cell cultures of NITE BP-03198, NITE BP-03199, NITE BP-03200, NITE BP-03201 and NITE BP-03202 are P. g. fungus, T. f. fungi and T. d. A circle of growth inhibition was formed in all of the fungal growth medium. Both bacterial cell cultures of Lactobacillus plantarum are P. g. fungus, T. f. fungi and T. d. It was shown that the growth of bacteria can be suppressed. On the other hand, the culture supernatant of the nisin A-producing strain was T. cerevisiae. d. Although it inhibited the growth of P. g. fungi and T. f. It was not possible to suppress the growth of bacteria.
[実験7:歯垢形成を促進する菌に対するラクトバチルス・プランタラムの抗菌活性評価試験]
NITE BP-03198、NITE BP-03199、NITE BP-03200、NITE BP-03201およびNITE BP-03202の菌体調製物が、歯垢形成を促進する菌の増殖を抑制するかを検証した。 [Experiment 7: Antibacterial activity evaluation test of Lactobacillus plantarum against bacteria that promotes plaque formation]
It was verified whether bacterial cell preparations of NITE BP-03198, NITE BP-03199, NITE BP-03200, NITE BP-03201 and NITE BP-03202 inhibit the growth of bacteria that promote plaque formation.
NITE BP-03198、NITE BP-03199、NITE BP-03200、NITE BP-03201およびNITE BP-03202の菌体調製物が、歯垢形成を促進する菌の増殖を抑制するかを検証した。 [Experiment 7: Antibacterial activity evaluation test of Lactobacillus plantarum against bacteria that promotes plaque formation]
It was verified whether bacterial cell preparations of NITE BP-03198, NITE BP-03199, NITE BP-03200, NITE BP-03201 and NITE BP-03202 inhibit the growth of bacteria that promote plaque formation.
実験7は、抗菌活性を検証する細菌として、ゴルドニ菌を用いたこと以外は、実験6と同様の方法で行った。表15に記載の培地および培養条件に従って、ゴルドニ菌を前培養した。ゴルドニ菌をGAM brothに懸濁し、McFarland No.0.5(約1×108~2×108cfu/mL)となるように調整した。これをさらに10倍希釈してゴルドニ菌の菌液11(約1×107~2×107cfu/mL)とした。100μLのゴルドニ菌の菌液11を測定用寒天培地12に滴下し、コンラージ棒で均一に塗布した。寒天培地の表面が乾いたら、10μLのラクトバチルス・プランタラムの菌体調製物13を滴下し、35℃で24時間培養した。ゴルドニ菌に対する抗菌活性の結果を表16に示す。ネガティブコントロールとして乳酸菌用培地(MRS Broth)を用いた。ポジティブコントロールとして、テトラサイクリン30μg/6mmφを含むセンシ・ディスク「TC」(日本ベクトン・ディッキンソン社製)を用いた。ATCC-11454は、ナイシンAを産生する乳酸菌(Lactococcus subsp.lactis)である。
Experiment 7 was performed in the same manner as Experiment 6, except that Goldoni bacteria were used as bacteria for verifying antibacterial activity. Gordonii was pre-cultured according to the medium and culture conditions described in Table 15. Gordonii bacteria were suspended in GAM broth and added to McFarland No. 0.5 (approximately 1×10 8 to 2×10 8 cfu/mL). This was further diluted 10-fold to obtain Gordonii fungus solution 11 (about 1×10 7 to 2×10 7 cfu/mL). 100 μL of the Gordonii fungus solution 11 was dropped on the agar medium 12 for measurement, and was evenly applied with a Conlarge stick. After the surface of the agar medium was dry, 10 µL of the cell preparation 13 of Lactobacillus plantarum was dropped and cultured at 35°C for 24 hours. Table 16 shows the results of the antibacterial activity against Gordonii. A medium for lactic acid bacteria (MRS Broth) was used as a negative control. As a positive control, Sensidisc "TC" (manufactured by Nippon Becton Dickinson Co., Ltd.) containing 30 μg/6 mmφ of tetracycline was used. ATCC-11454 is a nisin-A producing lactic acid bacterium (Lactococcus subsp. lactis).
NITE BP-03198、NITE BP-03199、NITE BP-03200、NITE BP-03201およびNITE BP-03202の菌体培養物はいずれも、ゴルドニ菌の生育培地に生育阻止円を形成させた。ラクトバチルス・プランタラムの菌体培養物は、ラクトバチルス・プランタラムの増殖を抑制できることが示された。
All of the cell cultures of NITE BP-03198, NITE BP-03199, NITE BP-03200, NITE BP-03201 and NITE BP-03202 formed growth inhibition circles in the growth medium of Gordonii fungus. It was shown that the cell culture of Lactobacillus plantarum can suppress the growth of Lactobacillus plantarum.
[実験8:口腔常在菌に対するラクトバチルス・プランタラムの抗菌活性評価試験]
NITE BP-03198、NITE BP-03199、NITE BP-03200、NITE BP-03201およびNITE BP-03202の菌体調製物が、口腔常在菌の増殖を抑制するかを検証した。 [Experiment 8: Antibacterial activity evaluation test of Lactobacillus plantarum against oral bacteria]
It was verified whether the cell preparations of NITE BP-03198, NITE BP-03199, NITE BP-03200, NITE BP-03201 and NITE BP-03202 suppress the growth of oral flora.
NITE BP-03198、NITE BP-03199、NITE BP-03200、NITE BP-03201およびNITE BP-03202の菌体調製物が、口腔常在菌の増殖を抑制するかを検証した。 [Experiment 8: Antibacterial activity evaluation test of Lactobacillus plantarum against oral bacteria]
It was verified whether the cell preparations of NITE BP-03198, NITE BP-03199, NITE BP-03200, NITE BP-03201 and NITE BP-03202 suppress the growth of oral flora.
実験8は、抗菌活性を検証する細菌として、サリバリウス菌を用いたこと以外は、実験6と同様の方法で行った。表17に記載の培地および培養条件に従って、サリバリウス菌を前培養した。サリバリウス菌をGAM brothに懸濁し、McFarland No.0.5(約1×108~2×108cfu/mL)となるように調整した。これをさらに10倍希釈してサリバリウス菌の菌液11(約1×107~2×107cfu/mL)とした。100μLのサリバリウス菌の菌液11を測定用寒天培地12に滴下し、コンラージ棒で均一に塗布した。寒天培地の表面が乾いたら、10μLのラクトバチルス・プランタラムの菌体調製物13を滴下し、35℃で24時間培養した。サリバリウス菌に対する抗菌活性の結果を表18に示す。ネガティブコントロールとして乳酸菌用培地(MRS Broth)を用いた。ポジティブコントロールとして、テトラサイクリン30μg/6mmφを含むセンシ・ディスク「TC」(日本ベクトン・ディッキンソン社製)を用いた。ATCC-11454は、ナイシンAを産生する乳酸菌(Lactococcus subsp.lactis)である。
Experiment 8 was carried out in the same manner as Experiment 6, except that B. salivarius was used as the bacterium for verifying the antibacterial activity. B. salivarius was pre-cultured according to the medium and culture conditions described in Table 17. Salivarius was suspended in GAM broth and plated with McFarland No. 0.5 (approximately 1×10 8 to 2×10 8 cfu/mL). This was further diluted 10-fold to obtain Salivarius bacterial solution 11 (approximately 1×10 7 to 2×10 7 cfu/mL). 100 μL of the bacterial solution 11 of Salivarius salivarius was dropped on the agar medium 12 for measurement, and was evenly applied with a Conlarge stick. After the surface of the agar medium was dry, 10 µL of the cell preparation 13 of Lactobacillus plantarum was dropped and cultured at 35°C for 24 hours. Table 18 shows the results of antibacterial activity against S. salivarius. A medium for lactic acid bacteria (MRS Broth) was used as a negative control. As a positive control, Sensidisc "TC" (manufactured by Nippon Becton Dickinson Co., Ltd.) containing 30 μg/6 mmφ of tetracycline was used. ATCC-11454 is a nisin-A producing lactic acid bacterium (Lactococcus subsp. lactis).
NITE BP-03198、NITE BP-03199、NITE BP-03200、NITE BP-03201およびNITE BP-03202の菌体培養物はいずれも、サリバリウス菌の生育培地に生育阻止円を形成させなかった。ラクトバチルス・プランタラムの菌体培養物は、口腔常在菌への影響が少ないことが示された。一方、テトラサイクリンは、口腔常在菌の増殖も抑制した。
None of the cell cultures of NITE BP-03198, NITE BP-03199, NITE BP-03200, NITE BP-03201 and NITE BP-03202 caused growth inhibition circles to form in the growth medium of Salivarius. It was shown that the bacterial cell culture of Lactobacillus plantarum has little effect on oral flora. On the other hand, tetracycline also suppressed the growth of oral flora.
11 歯周病の原因菌、歯垢形成を促進する菌又は口腔常在菌の菌液、12 測定用寒天培地、13 ラクトバチルス・プランタラムの菌体調製物、14 生育阻止円。
11. Bacteria that cause periodontal disease, bacteria that promote plaque formation, or fungal fluids of oral bacteria, 12. Agar medium for measurement, 13. Lactobacillus plantarum bacterial cell preparation, 14. Growth inhibition circle.
Claims (13)
- ラクトバチルス・プランタラムの菌体もしくは菌体培養物またはこれらの抽出物を含む口腔用組成物。 An oral composition containing Lactobacillus plantarum cells or cell cultures or extracts thereof.
- 食品である、請求項1に記載の組成物。 The composition according to claim 1, which is a food.
- 前記食品は発酵食品である、請求項2に記載の組成物。 The composition according to claim 2, wherein the food is a fermented food.
- 洗口剤または歯磨剤である、請求項1に記載の組成物。 The composition according to claim 1, which is a mouthwash or dentifrice.
- フッ素化合物をさらに含む、請求項1または4に記載の組成物。 The composition according to claim 1 or 4, further comprising a fluorine compound.
- 前記ラクトバチルス・プランタラムは、NITE-BP-03198、NITE-BP-03199、NITE-BP-03200、NITE-BP-03201およびNITE-BP-03202から選択される少なくとも1つである、請求項1または2に記載の組成物。 Claim 1, wherein the Lactobacillus plantarum is at least one selected from NITE-BP-03198, NITE-BP-03199, NITE-BP-03200, NITE-BP-03201 and NITE-BP-03202. Or the composition according to 2.
- 口腔内疾患の予防または治療用組成物である、請求項1~4のいずれか1項に記載の組成物。 The composition according to any one of claims 1 to 4, which is a composition for preventing or treating oral diseases.
- 前記口腔内疾患は歯周病である、請求項7に記載の組成物。 The composition according to claim 7, wherein the oral disease is periodontal disease.
- ラクトバチルス・プランタラムの菌体もしくは菌体培養物またはこれらの抽出物を動物の口腔に適用することを含む、口腔内疾患の予防または治療方法。 A method for preventing or treating oral diseases, which comprises applying Lactobacillus plantarum cells or cell cultures or extracts thereof to the oral cavity of animals.
- 前記口腔内疾患は歯周病である、請求項9に記載の方法。 The method according to claim 9, wherein the oral disease is periodontal disease.
- ラクトバチルス・プランタラムの菌体もしくは菌体培養物またはこれらの抽出物を含む、歯周病の原因菌に対する増殖抑制剤または殺菌剤。 A growth inhibitor or bactericidal agent for periodontal disease-causing bacteria containing Lactobacillus plantarum cells or cell cultures or extracts thereof.
- 前記歯周病の原因菌は、ポルフィロモナス・ジンジバリス、タンネレラ・フォーサイシアおよびトレポネーマ・デンティコーラから選択される少なくとも1つを含む、請求項11に記載の増殖抑制剤または殺菌剤。 The growth inhibitor or bactericide according to claim 11, wherein the periodontal disease-causing bacteria include at least one selected from Porphyromonas gingivalis, Tannerella forsythia and Treponema denticola.
- ラクトバチルス・プランタラムの菌体もしくは菌体培養物またはこれらの抽出物を歯周病の原因菌に接触させることを含む、歯周病菌の増殖抑制または殺菌方法。 A method for inhibiting the growth of or sterilizing periodontal disease bacteria, comprising contacting Lactobacillus plantarum cells or cell cultures or extracts thereof with periodontal disease-causing bacteria.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023533205A JPWO2023282356A1 (en) | 2021-07-09 | 2022-07-08 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021114164 | 2021-07-09 | ||
JP2021-114164 | 2021-07-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023282356A1 true WO2023282356A1 (en) | 2023-01-12 |
Family
ID=84800793
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/027147 WO2023282356A1 (en) | 2021-07-09 | 2022-07-08 | Oral composition and prophylactic or treatment method for diseases of the oral cavity |
Country Status (2)
Country | Link |
---|---|
JP (1) | JPWO2023282356A1 (en) |
WO (1) | WO2023282356A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7429076B1 (en) | 2023-04-04 | 2024-02-07 | ウィステリア製薬株式会社 | Powder containing lactic acid bacteria, disinfectant, oral care agent |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014000039A (en) * | 2012-06-19 | 2014-01-09 | Lion Corp | Lactobacillus and substance from cultivation thereof, and composition containing these |
WO2022004515A1 (en) * | 2020-06-29 | 2022-01-06 | 住友化学株式会社 | Novel microorganism belonging to genus lactobacillus, and agent and method for controlling plant disease caused by ralstonia solanacearum or ralstonia pseudosolanacearum |
-
2022
- 2022-07-08 WO PCT/JP2022/027147 patent/WO2023282356A1/en active Application Filing
- 2022-07-08 JP JP2023533205A patent/JPWO2023282356A1/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014000039A (en) * | 2012-06-19 | 2014-01-09 | Lion Corp | Lactobacillus and substance from cultivation thereof, and composition containing these |
WO2022004515A1 (en) * | 2020-06-29 | 2022-01-06 | 住友化学株式会社 | Novel microorganism belonging to genus lactobacillus, and agent and method for controlling plant disease caused by ralstonia solanacearum or ralstonia pseudosolanacearum |
Non-Patent Citations (1)
Title |
---|
R. TEANPAISAN, S. PIWAT, G. DAHLÉN: "Inhibitory effect of oral Lactobacillus against oral pathogens", LETTERS IN APPLIED MICROBIOLOGY, PUBLISHED FOR THE SOCIETY FOR APPLIED BACTERIOLOGY BY BLACKWELL SCIENTIFIC PUBLICATIONS, vol. 53, no. 4, 1 October 2011 (2011-10-01), pages 452 - 459, XP055047020, ISSN: 02668254, DOI: 10.1111/j.1472-765X.2011.03132.x * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7429076B1 (en) | 2023-04-04 | 2024-02-07 | ウィステリア製薬株式会社 | Powder containing lactic acid bacteria, disinfectant, oral care agent |
Also Published As
Publication number | Publication date |
---|---|
JPWO2023282356A1 (en) | 2023-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5732387B2 (en) | Uses and methods for preventing and / or treating halitosis | |
KR101900992B1 (en) | Prophylactic or therapeutic agent for oral diseases | |
JP5721765B2 (en) | Uses and methods for preventing and / or treating caries caused by mutans streptococci | |
US9763988B2 (en) | Nano-sized kimchi lactic acid bacteria | |
EP2420580A1 (en) | Probiotic composition for oral health | |
CN101948773A (en) | Be used to prevent and/or treat the means and the method for carious tooth | |
JP2020092704A (en) | Novel lactic acid bacterium strain and immunostimulant containing the same | |
US10517907B2 (en) | Anticariogenic agent and anticariogenic composition | |
WO2023282356A1 (en) | Oral composition and prophylactic or treatment method for diseases of the oral cavity | |
KR102095339B1 (en) | Novel lactobacillus reuteri and composition for preventing or treating periodontal diseases comprising the same | |
JP6744542B2 (en) | Method for culturing Lactobacillus Lactobacillus | |
JP5544234B2 (en) | Composition for inhibiting periodontal disease growth | |
JP2024065261A (en) | Skin condition improving agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22837770 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023533205 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22837770 Country of ref document: EP Kind code of ref document: A1 |